Protein,Protein_definition,Trait_category,Trait,sample_size,Estimated_effect,se,lowerCI,upperCI,Pvalue
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1050.Time spend outdoors in summer,48529,0.0124838857058508,0.0193558786940046,-0.0254536365343982,0.0504214079460998,0.518955148741053
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1060.Time spent outdoors in winter,44853,-0.0328717777415274,0.0220372038836237,-0.0760646973534298,0.0103211418703751,0.135806157380355
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X1070.Time spent watching television (TV),49675,0.096633319586663,0.0191886957837453,0.0590234758505223,0.134243163322804,4.78684246934194e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X1080.Time spent using computer,44767,-0.0171951826410127,0.0209246617025895,-0.0582075195780881,0.0238171542960627,0.41121926636114
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X1090.Time spent driving,43677,0.0478705243031084,0.0216899723607236,0.00535817847609017,0.0903828701301266,0.0273230470967368
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1160.Sleep duration,51446,-0.000307123454044222,0.018004944245622,-0.0355968141754634,0.0349825672673749,0.986390684983211
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#0.Location of pain during the past week_None of the given areas,34321,0.0162038926973015,0.0196544172841083,-0.0223187651795507,0.0547265505741538,0.409708249963162
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#1.Location of pain during the past week_Left shoulder,34321,0.0336261511318154,0.0193512518442795,-0.0043023024829725,0.0715546047466032,0.0822978475423615
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#10.Location of pain during the past week_Upper right leg,34321,0.0164116942283843,0.0227606885978845,-0.0281992554234694,0.061022643880238,0.470892170426911
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#11.Location of pain during the past week_Lower left leg,34321,0.00541847816599794,0.0235457586197918,-0.0407312087287939,0.0515681650607898,0.817998793292185
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#12.Location of pain during the past week_Lower right leg,34321,0.0116964484136714,0.0243145339264684,-0.0359600380822068,0.0593529349095495,0.630492723139648
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#13.Location of pain during the past week_Left jaw pain,34321,-0.0174822203255951,0.0466901008302616,-0.108994817952908,0.0740303773017176,0.708091285354841
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#14.Location of pain during the past week_Right jaw pain,34321,-0.0581623910985152,0.0482569607749489,-0.152746034217415,0.0364212520203847,0.228128557335368
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#15.Location of pain during the past week_Chest pain,34321,-0.0239344911976978,0.033746720676555,-0.0900780637237455,0.0422090813283499,0.478191967389626
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#16.Location of pain during the past week_Abdomen,34321,-0.02600916871535,0.0249976339909503,-0.0750045313376126,0.0229861939069127,0.298147861357742
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#17.Location of pain during the past week_Neck pain,34321,0.0157285781486302,0.0175543765627734,-0.0186779999144057,0.0501351562116662,0.370277738513407
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#18.Location of pain during the past week_Upper back,34321,0.0231124289470493,0.0248692017237719,-0.0256312064315436,0.0718560643256422,0.352724251879233
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#19.Location of pain during the past week_Lower back,34321,0.00679394364149958,0.0142650499488179,-0.0211655542581835,0.0347534415411827,0.633895562213253
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#2.Location of pain during the past week_Right shoulder,34321,-0.0075846347978341,0.01836854324889,-0.0435869795656585,0.0284177099699903,0.67967784161585
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#3.Location of pain during the past week_Upper left arm,34321,0.0353762220651156,0.0278341927452617,-0.0191787957155974,0.0899312398458286,0.203770163136962
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#4.Location of pain during the past week_Upper right arm,34321,-0.0102860296499374,0.0264095472765304,-0.062048742311937,0.0414766830120622,0.696927933938573
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#5.Location of pain during the past week_Lower left arm,34321,0.0120206322250362,0.0324903876376089,-0.0516605275446773,0.0757017919947497,0.711408583333589
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#6.Location of pain during the past week_Lower right arm,34321,-0.047878329273393,0.0308046791621424,-0.108255500431192,0.0124988418844061,0.120153833183913
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#7.Location of pain during the past week_Left hip,34321,-0.0211560604972915,0.0204782131469057,-0.0612933582652266,0.0189812372706437,0.301580563327544
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#8.Location of pain during the past week_Right hip,34321,0.0170238189159335,0.0195371902149061,-0.0212690739052825,0.0553167117371494,0.383580609095722
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120039#9.Location of pain during the past week_Upper left leg,34321,-0.00573971303950663,0.0239645856918103,-0.0527103009954548,0.0412308749164416,0.810716287537123
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120040.Fatigue severity over the past week,34329,0.106391954954669,0.0303085336673885,0.0469872289665879,0.165796680942751,0.000449489341586396
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120041.Waking unrefreshed severity over the past week,34331,0.0851497437987686,0.0298352443039214,0.0266726649630828,0.143626822634455,0.00432574726609387
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120042.Cognitive symptoms severity over the past week,34329,0.0436904915669615,0.0329051158139271,-0.0208035354283356,0.108184518562259,0.184282393146303
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120098.Mobility problems today,34334,0.0160092801508245,0.0372535644402296,-0.0570077061520255,0.0890262664536744,0.667394926806673
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120099.Self-care problems today,34334,-0.0467743574831614,0.0583475507121233,-0.161135556878923,0.0675868419126003,0.422773206504458
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120100.Problems doing usual activities,34334,0.0114203265641387,0.0349723188692159,-0.0571254184195244,0.0799660715478018,0.744012287166449
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120101.Pain or discomfort today,34334,0.0358089168585947,0.0303450776192295,-0.0236674352750951,0.0952852689922846,0.238004410498503
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120102.Anxiety or depression today,34334,0.0365412265645349,0.0359246973924066,-0.033871180324582,0.106953633453652,0.309100009896518
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120103.Scale to indicate how health is today,34303,-0.000409307998082571,0.00618850816419962,-0.0125387839999138,0.0117201680037487,0.94726762247341
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120104.Little interest or pleasure in doing things over the last two weeks,34319,0.013953148212793,0.0360372121182633,-0.0566797875390031,0.084586083964589,0.698625485367665
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X120105.Feeling down, depressed, or hopeless over the last two weeks",34303,0.0165603605642144,0.0368240408866699,-0.0556147595736586,0.0887354807020874,0.652924564881036
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X120106.Trouble falling or staying asleep, or sleeping too much over the last two weeks",34323,0.0744980332501147,0.0297913451788841,0.0161069966995018,0.132889069800728,0.01241137735892
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120107.Feeling tired or having little energy over the last two weeks,34323,0.0870537903893181,0.0306323589847509,0.0270143667792063,0.14709321399943,0.00449337332928271
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120108.Poor appetite or overeating over the last two weeks,34320,0.0775627158122267,0.0373982990166554,0.00426204973958214,0.150863381884871,0.0381070923931546
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120109.Feeling bad about self over the last two weeks,34296,0.0390141940229098,0.0380295539693958,-0.0355237317571059,0.113552119802926,0.304966538650648
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120110.Trouble concentrating over the last two weeks,34326,0.0451886113345302,0.0381964727721656,-0.0296764752989144,0.120053697967975,0.236813364882635
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120111.Moving or speaking slower or faster than usual over the last two weeks,34311,0.0730108635806502,0.0568465072442731,-0.0384082906181251,0.184430017779426,0.199047673808512
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X120112.Thoughts of being better off dead or of hurting self over the last two weeks,34258,0.0647360765079058,0.0741871280959845,-0.0806706945602238,0.210142847576035,0.382898438247618
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X120113.Level of difficultly depression has made to do work, take care of things at home, or get along with other people",31348,-0.0123319572118533,0.0404121177790078,-0.0915397080587085,0.0668757936350019,0.760256636155797
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1269.Exposure to tobacco smoke at home,48433,0.0562754124380018,0.0427226819382491,-0.0274610441609664,0.14001186903697,0.18777528169086
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1279.Exposure to tobacco smoke outside home,47159,0.0510341887571858,0.0261549059799413,-0.000229426963499216,0.102297804477871,0.0510418803227581
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1289.Cooked vegetable intake,50447,-0.0017094904428243,0.0185775908953504,-0.0381215685977111,0.0347025877120625,0.92668367535141
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1299.Salad  or  raw vegetable intake,49919,-0.101941708656511,0.0197164847433523,-0.140586018753481,-0.0632973985595404,2.35344123378911e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1309.Fresh fruit intake,50427,0.0525405141120696,0.0197478429547565,0.0138347419207469,0.0912462863033924,0.00780554236816155
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1319.Dried fruit intake,48894,-0.0252875565721068,0.0209019978228157,-0.0662554723048256,0.0156803591606119,0.226361201907187
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X134.Number of self-reported cancers,51670,-0.00161964985471996,0.0413003901393429,-0.0825684145278321,0.0793291148183922,0.968718193293809
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X135.Number of self-reported non-cancer illnesses,51670,0.106471881654641,0.0180822941774265,0.0710305850668849,0.141913178242397,3.94943331659171e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X136.Number of operations, self-reported",51670,0.0126487234788924,0.0180806781088707,-0.0227894056144941,0.0480868525722789,0.484200922948257
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X137.Number of treatments or medications taken,51670,0.110067375269384,0.0181173542559964,0.0745573609276314,0.145577389611137,1.25404424914079e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1438.Bread intake,50804,0.00229461754249404,0.00393685710667385,-0.00542162238658671,0.0100108574715748,0.559995675254743
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1458.Cereal intake,50054,0.0739297816740143,0.0186088198941303,0.0374564946815188,0.11040306866651,7.12120794444082e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1488.Tea intake,50589,0.00617608138533326,0.00372235999016476,-0.00111974419538967,0.0134719069660562,0.097090385238886
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1498.Coffee intake,49360,-0.0158071832041619,0.0188225539269899,-0.052699388901062,0.0210850224927383,0.401028335099571
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X1528.Water intake,49693,-0.102180714573411,0.0191728938085895,-0.139759586438246,-0.0646018427085753,9.93435503766252e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1568.Average weekly red wine intake,42745,-0.129675106532228,0.0217821500988879,-0.172368120726048,-0.0869820923384075,2.67480218725149e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1578.Average weekly champagne plus white wine intake,42737,-0.120595310243653,0.0224030294772736,-0.164505248019109,-0.0766853724681964,7.41325670239114e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1588.Average weekly beer plus cider intake,42782,-0.04796776858197,0.0244317347088144,-0.0958539686112462,-8.15685526938392e-05,0.0496214634451521
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1598.Average weekly spirits intake,42704,0.0149477492379751,0.0244188216147672,-0.0329131411269686,0.0628086396029188,0.540452201884066
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1608.Average weekly fortified wine intake,42774,0.128111504137045,0.0430783457155266,0.0436779465346133,0.212545061739478,0.00294393747232708
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X1737.Childhood sunburn occasions,45233,-0.0193477420403703,0.0216418057201987,-0.0617656812519598,0.0230701971712192,0.371332756116251
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1807.Father's age at death,40455,-0.0144509582268488,0.00528778023951255,-0.0248150074962934,-0.00408690895740417,0.00628464521471904
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1845.Mother's age,39710,-0.000659386715329642,0.00798543290962816,-0.0163108352182008,0.0149920617875416,0.93419155950119
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1873.Number of full brothers,51171,0.0394018914841634,0.0180354733840122,0.0040523636514995,0.0747514193168273,0.0289201643067164
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X1883.Number of full sisters,51172,0.0329269051218709,0.0182454186376511,-0.00283411540792532,0.0686879256516671,0.0711378157255565
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20015.Sitting height,51442,-0.0175921797186263,0.00497913131129084,-0.0273512770887563,-0.00783308234849626,0.000411259890004524
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20016.Fluid intelligence score,32612,-0.0458675144039914,0.0301314372726817,-0.104925131458448,0.0131901026504648,0.127983177216479
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20018.Prospective memory result,32936,0.00662586235882138,0.0433176436510507,-0.078276719197238,0.0915284439148808,0.878433300452637
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20019.Speech-reception-threshold (SRT) estimate (left),32524,0.0118996491939068,0.00699149153666398,-0.00180367421795459,0.0256029726057682,0.0887877417431915
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20021.Speech-reception-threshold (SRT) estimate (right),32516,0.0135044109743283,0.00695311037938222,-0.000123685369260896,0.0271325073179174,0.0521438955958472
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20023.Mean time to correctly identify matches,51361,0.0103515988488673,0.00396389783746434,0.00258235908743715,0.0181208386102974,0.00902029443662526
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#1.Illnesses of father_Heart disease,48451,0.0186988836851613,0.00861772644777681,0.00180813984751873,0.0355896275228038,0.0300303047746352
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#10.Illnesses of father_Alzheimer's disease or dementia,48023,0.0122352601400984,0.0195593416952278,-0.0261010495825481,0.050571569862745,0.531618937737612
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#11.Illnesses of father_Parkinson's disease,47989,0.0270314557714787,0.026089989119549,-0.0241049229028373,0.0781678344457948,0.30017270462475
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#12.Illnesses of father_Severe depression,48019,0.0172878484246441,0.0201208498102373,-0.0221490172034209,0.0567247140527091,0.390238317233663
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#13.Illnesses of father_Prostate cancer,48023,0.0017899720513632,0.0147098208807983,-0.0270412768750014,0.0306212209777278,0.903149101430653
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#2.Illnesses of father_Stroke,48181,0.0157610851077891,0.0113065453738835,-0.00639974382502247,0.0379219140406007,0.163336727151077
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#3.Illnesses of father_Lung cancer,48119,-0.0143071823773676,0.0147040431877973,-0.0431271070254502,0.0145127422707151,0.33055798928416
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#4.Illnesses of father_Bowel cancer,48027,-0.0189694368063297,0.0177626207249934,-0.0537841734273168,0.0158452998146574,0.285557644960036
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#6.Illnesses of father_Chronic bronchitis or emphysema,48149,0.0166300684956077,0.0140186360601092,-0.0108464581822063,0.0441065951734217,0.23552219374845
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#8.Illnesses of father_High blood pressure,48303,0.0156290785162231,0.00889950578812375,-0.00181395282849943,0.0330721098609457,0.0790712664104267
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20107#9.Illnesses of father_Diabetes,48153,0.0244441935818779,0.0121493604553363,0.000631447089418768,0.0482569400743371,0.044233729290815
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#1.Illnesses of mother_Heart disease,49502,0.0347238553251325,0.010283470433157,0.0145682532761448,0.0548794573741202,0.000734787626285436
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#10.Illnesses of mother_Alzheimer's disease or dementia,49375,0.00245596524867406,0.0166846167448142,-0.0302458835711617,0.0351578140685098,0.882975812598424
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#11.Illnesses of mother_Parkinson's disease,49319,0.0191988940677378,0.0352182876796028,-0.0498289497842837,0.0882267379197592,0.585662073213533
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#12.Illnesses of mother_Severe depression,49365,0.0409192824890609,0.0150240397360903,0.0114721646063238,0.0703664003717979,0.00646211059615558
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#2.Illnesses of mother_Stroke,49446,0.0142753293913245,0.0122048275058955,-0.00964613252023074,0.0381967913028797,0.242154296407857
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#3.Illnesses of mother_Lung cancer,49372,-0.00236458669226721,0.0198900742759947,-0.0413491322732169,0.0366199588886825,0.90536918575326
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#4.Illnesses of mother_Bowel cancer,49348,-0.00215183449596486,0.0188792911609367,-0.0391552451714009,0.0348515761794711,0.909255683875306
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#5.Illnesses of mother_Breast cancer,49384,0.0136013234504457,0.0142957065289668,-0.0144182613463292,0.0416209082472205,0.341396587941049
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#6.Illnesses of mother_Chronic bronchitis or emphysema,49387,0.0101256772353458,0.0167343706500097,-0.0226736892386733,0.0429250437093649,0.545129464571564
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#8.Illnesses of mother_High blood pressure,49599,0.0167824657189444,0.00810448809558436,0.000897669051599093,0.0326672623862898,0.0383909905766606
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20110#9.Illnesses of mother_Diabetes,49438,0.0620043063189733,0.0125621400881118,0.0373825117462741,0.0866261008916726,8.03214982766329e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#1.Illnesses of siblings_Heart disease,46673,0.023090441282413,0.0165026578187473,-0.0092547680423317,0.0554356506071577,0.16176802121912
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#10.Illnesses of siblings_Alzheimer's disease or dementia,46561,0.0753100489681416,0.0915030601469374,-0.104035948919856,0.254656046856139,0.41049780552935
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#11.Illnesses of siblings_Parkinson's disease,46560,-0.0566591286558588,0.0782620089399843,-0.210052666178228,0.0967344088665103,0.469093323551823
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#12.Illnesses of siblings_Severe depression,46648,0.0237091322042101,0.0150949084936711,-0.00587688844338535,0.0532951528518055,0.116273015743052
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#13.Illnesses of siblings_Prostate cancer,46566,0.0660326030122252,0.0505283686825768,-0.0330029996056253,0.165068205630076,0.191279554764228
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#2.Illnesses of siblings_Stroke,46580,0.0123197000962385,0.0285957563243783,-0.043727982299543,0.06836738249202,0.666601401405444
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#3.Illnesses of siblings_Lung cancer,46568,0.0783091143248078,0.0383016659860157,0.00323784899221709,0.153380379657398,0.0409121844553128
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#4.Illnesses of siblings_Bowel cancer,46576,0.00400089196158455,0.0340022331610627,-0.0626434850340984,0.0706452689572675,0.906333692982205
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#5.Illnesses of siblings_Breast cancer,46581,-0.0594432626168546,0.0227355731403949,-0.104004985972029,-0.0148815392616806,0.00894043958097416
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#6.Illnesses of siblings_Chronic bronchitis or emphysema,46585,0.0667099902895702,0.0299887414491385,0.00793205704925876,0.125487923529882,0.02612452781722
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#8.Illnesses of siblings_High blood pressure,46768,0.00305887315401484,0.0106359023675974,-0.0177874954864761,0.0239052417945058,0.773656436570559
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X20111#9.Illnesses of siblings_Diabetes,46660,0.0221416983543091,0.0155499303317357,-0.00833616509589284,0.052619561804511,0.154486266337937
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20127.Neuroticism score,46197,0.0428172443492497,0.0188516381021738,0.00586803366898894,0.0797664550295104,0.0231398444108631
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20128.Number of fluid intelligence questions attempted within time limit,32612,0.0195784902409158,0.0305969216051691,-0.0403914761052157,0.0795484565870474,0.522264582106145
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X20161.Pack years of smoking,31520,0.0591175322913307,0.00830268744531704,0.0428442648985093,0.0753907996841521,1.17466201045338e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X20162.Pack years adult smoking as proportion of life span exposed to smoking,31520,0.0559251138276014,0.00776332760804513,0.0407089917158329,0.0711412359393698,6.41468908740093e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20191.Fluid intelligence score,31252,0.0198379592722736,0.0331622247562263,-0.04516000124993,0.0848359197944772,0.549718483044891
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20192.Number of fluid intelligence questions attempted within time limit,31252,0.0668855581369661,0.0339387154196695,0.000365675914413971,0.133405440359518,0.0487869773505827
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X20240.Maximum digits remembered correctly,30617,-0.0441008293289427,0.0352240924920392,-0.11314005061334,0.0249383919554541,0.210610504319411
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X20255.Spirometry QC measure,44670,0.0220024179780855,0.0240743150291097,-0.0251832394789696,0.0691880754351405,0.360760303994723
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X20261.avMSE,29838,-0.00536892069184665,0.00854865713017974,-0.0221242886669989,0.0113864472833056,0.530000036717352
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X20262.Myopia diagnosis,29838,0.0187929592218681,0.045170048207062,-0.0697403352639734,0.10732625370771,0.677388990888049
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X20280.Glucose-lactate,39545,0.00916304682203677,0.0050086780623286,-0.000653962180127277,0.0189800558242008,0.0673535647091948
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X20281.Spectrometer-corrected alanine,39581,0.0120402818305639,0.00495561944248386,0.00232726772329557,0.0217532959378323,0.0151257012419892
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20544#11.Mental health problems ever diagnosed by a professional_Depression,32518,0.0214894992236038,0.0240809684071793,-0.0257091988544676,0.0686881973016752,0.372211315130893
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20544#6.Mental health problems ever diagnosed by a professional_Panic attacks,32515,0.0511218785935729,0.0480701578932545,-0.0430956308772059,0.145339388064352,0.287591859421902
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20546#1.Substances taken for depression_Unprescribed medication (more than once),32513,0.0289911121032407,0.0536239442173219,-0.0761118185627103,0.134094042769192,0.588771419817909
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20546#3.Substances taken for depression_Medication prescribed to you (for at least two weeks),32513,0.0148345677868501,0.0232285402933067,-0.030693371188031,0.0603625067617311,0.523077058423958
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20546#4.Substances taken for depression_Drugs or alcohol (more than once),32513,-0.0235618674953963,0.0375177962795187,-0.097096748203253,0.0499730132124604,0.530008440927128
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#1.Manifestations of mania or irritability_I was more talkative than usual,32521,-0.00601142807288855,0.0486902451626379,-0.101444308591659,0.0894214524458817,0.901743591416772
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#2.Manifestations of mania or irritability_I was more restless than usual,32521,-0.0355165294504005,0.0317887397177903,-0.0978224592972696,0.0267894003964686,0.263910909133155
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#3.Manifestations of mania or irritability_My thoughts were racing,32521,0.0562934679684611,0.0346271999199543,-0.0115758438746494,0.124162779811572,0.104049694213339
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#5.Manifestations of mania or irritability_I needed less sleep than usual,32521,-0.0584859983170729,0.0537542611737471,-0.163844350217617,0.0468723535834715,0.276614196356406
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#6.Manifestations of mania or irritability_I was more creative or had more ideas than usual,32521,0.0223010179210529,0.0618514977514972,-0.0989279176718817,0.143529953513987,0.718439099994362
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#7.Manifestations of mania or irritability_I was easily distracted,32521,0.0343249821973871,0.0357099629027165,-0.0356665450919372,0.104316509486711,0.33647048434378
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#8.Manifestations of mania or irritability_I was more confident than usual,32521,0.0246719847600811,0.0609686463193313,-0.0948265620258083,0.14417053154597,0.685732469583557
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20548#9.Manifestations of mania or irritability_I was more active than usual,32521,0.0161957718337169,0.0463821299526795,-0.0747132028735349,0.107104746540969,0.726961702639837
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20549#1.Substances taken for anxiety_Unprescribed medication (more than once),32523,0.0817430555732444,0.0630512551910974,-0.0418374046013066,0.205323515747795,0.19485363210899
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20549#3.Substances taken for anxiety_Medication prescribed to you (for at least two weeks),32523,-0.00269604890179067,0.0310677400231341,-0.0635888193471335,0.0581967215435521,0.930848635982935
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20549#4.Substances taken for anxiety_Drugs or alcohol (more than once),32523,-0.108059335763203,0.0426378748600613,-0.191629570488923,-0.0244891010374829,0.0112830471440648
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X20553#4.Methods of self-harm used_Ingesting a medication in excess of the normal dose,32523,0.0485855441837119,0.0708454913434449,-0.0902716188494401,0.187442707216864,0.492860203479918
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20600.Liking for adding salt to foods,35202,-0.0220258781881894,0.0267923201985698,-0.0745388257773862,0.0304870694010073,0.411039155149273
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20601.Liking for aniseed,35202,0.00988059242318142,0.0265763882468085,-0.0422091285405632,0.0619703133869261,0.710062967615412
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20602.Liking for apple juice,35202,0.108375133584603,0.0268475338265037,0.0557539672846561,0.160996299884551,5.4567493389667e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20603.Liking for apples,35202,0.02512575715035,0.0273194185515309,-0.0284203032106505,0.0786718175113505,0.357747445402312
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20604.Liking for asparagus,35202,-0.140418224102622,0.0271897062242913,-0.193710048302233,-0.0871263999030114,2.45318453755263e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20605.Liking for aubergine,35202,-0.119893711644501,0.0268801121905621,-0.172578731538002,-0.0672086917509991,8.26280304516879e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20606.Liking for avocados,35202,-0.134244977058006,0.0271064133440397,-0.187373547212323,-0.0811164069036878,7.43159337103121e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20607.Liking for bacon,35202,0.00503717977555863,0.0270619217431334,-0.0480041868409828,0.0580785463921,0.852341966888795
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20608.Liking for baked or steamed fish,35202,-0.0147793882917523,0.0272048366809207,-0.0681008681863568,0.0385420916028522,0.586959240589697
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20609.Liking for bananas,35202,0.113458051661286,0.0278870534257364,0.0587994269468425,0.168116676375729,4.76404979524179e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20610.Liking for barbequed or grilled meat,35202,-0.049959516604491,0.0269709414491017,-0.10282256184473,0.00290352863574841,0.0640021327034542
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20611.Liking for beef steak,35202,-0.0280213997297655,0.0269792976383571,-0.0809008231009453,0.0248580236414143,0.299000871851588
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20612.Liking for beetroot,35202,0.0184406514070538,0.0272404488583497,-0.0349506283553117,0.0718319311694193,0.498446148951617
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20613.Liking for bell pepper,35202,-0.0285764359102725,0.0272446014410181,-0.081975854734668,0.024822982914123,0.294253719020193
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20614.Liking for bicycling,35202,-0.101426749904144,0.0269648211519509,-0.154277799361967,-0.0485757004463199,0.000169783653138972
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20615.Liking for biscuits,35202,0.159182160023857,0.0270773702587107,0.106110514316784,0.21225380573093,4.24927414685019e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20616.Liking for bitter foods,35202,-0.100721927190096,0.0268922937715578,-0.153430822982349,-0.048013031397843,0.000181011470072077
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20617.Liking for bitter or ale,35202,-0.0765607850700818,0.0274095490607195,-0.130283501229092,-0.0228380689110716,0.00522744057888384
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20618.Liking for black olives,35202,-0.119687283048685,0.0269782126437354,-0.172564579830406,-0.0668099862669636,9.23204569981602e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20619.Liking for black pepper,35202,-0.0863509166112655,0.0270841297185739,-0.13943581085967,-0.0332660223628606,0.00143526862572898
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20620.Liking for blue cheese,35202,-0.0652996725894859,0.0269956808388161,-0.118211207033565,-0.0123881381454064,0.0155834518056513
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20621.Liking for bolognese sauce,35202,0.0233349886581052,0.0269458215011275,-0.0294788214841047,0.0761487988003152,0.386510382018834
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20622.Liking for broad beans,35202,-0.102348395696404,0.0268567377185343,-0.154987601624731,-0.0497091897680765,0.00013919296638392
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20623.Liking for broccoli,35202,-0.0197001800764742,0.0278210835387754,-0.074229503812474,0.0348291436595256,0.47889614164295
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20624.Liking for brown rice,35202,0.00694781429390776,0.026972995615223,-0.0459192571119293,0.0598148856997448,0.796732593282013
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20625.Liking for brussel sprouts,35202,0.00197428231220643,0.0272585897514737,-0.051452553600682,0.0554011182250948,0.942262663152581
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20626.Liking for burgers (meat),35202,-0.0282534426806566,0.02697602208004,-0.0811264459575349,0.0246195605962218,0.294958708536866
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20627.Liking for burn of spicy foods,35202,-0.102946636056483,0.0269405265631032,-0.155750068120165,-0.0501432039928007,0.00013348346174186
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20628.Liking for butter on bread,35202,0.0606908312132354,0.0273897075357421,0.00700700444318097,0.11437465798329,0.0267232018648268
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20629.Liking for butternut squash,35202,-0.0451693284324252,0.0268206271473044,-0.0977377576411418,0.00739910077629138,0.0921847652045277
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20630.Liking for cabbage,35202,-0.0279656113685378,0.0274274492310601,-0.0817234118614156,0.02579218912434,0.307929865638344
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20631.Liking for cake,35202,0.151151978543025,0.0271302940592061,0.0979766021869811,0.204327354899069,2.58562666236976e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20632.Liking for cake icing,35202,0.154150482837435,0.0269198073571968,0.10138766041733,0.206913305257541,1.0526304413767e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20633.Liking for capers,35202,-0.135628220626001,0.0268800474531541,-0.188313113634183,-0.0829433276178191,4.58907008137944e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20634.Liking for cauliflower,35202,-0.00183913833823182,0.0274381012979885,-0.0556178168822892,0.0519395402058256,0.946560093442279
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20635.Liking for cereal or granola bar,35202,0.104932773546676,0.0269002910328834,0.0522082031222243,0.157657343971127,9.64273782932223e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20636.Liking for cheesecake,35202,0.140495765821015,0.0268755601089188,0.0878196680075342,0.193171863634496,1.74741589759461e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20637.Liking for cherries,35202,0.0162863522722678,0.0280488745134912,-0.038689441774175,0.0712621463187105,0.561493360511917
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20638.Liking for chicken,35202,0.0380392806874043,0.028158996743161,-0.0171523529291912,0.0932309143039998,0.17676249330655
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20639.Liking for chilli pepper,35202,-0.133551150485392,0.0269406156390176,-0.186354757137866,-0.0807475438329174,7.25357057255422e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20640.Liking for chips or french fries,35202,0.053053663722809,0.0271162727914526,-9.4230948438162e-05,0.106201558394056,0.0504278710766556
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20641.Liking for cigarette smoking,35202,0.0173530488345544,0.0424168154775952,-0.0657839095015322,0.100490007170641,0.682468304562772
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20642.Liking for cod,35202,0.0102963509396624,0.0276646469871731,-0.0439263571551969,0.0645190590345216,0.709762494987037
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20643.Liking for coffee with sugar,35202,0.0750693048191427,0.0293649498471718,0.017514003118686,0.132624606519599,0.010588292891207
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20644.Liking for coffee without sugar,35202,-0.0934439504937648,0.0272366805637178,-0.146827844398652,-0.0400600565888779,0.000603922199171937
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20645.Liking for coriander,35202,-0.0907591541438462,0.0267627111762692,-0.143214068049334,-0.0383042402383586,0.000698112244568651
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20646.Liking for corn flakes,35202,0.173161966317391,0.0269619968148811,0.120316452560224,0.226007480074558,1.39468504562439e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20647.Liking for cream,35202,0.0648714019003049,0.0267050113603681,0.0125295796339833,0.117213224166626,0.0151482644993163
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20648.Liking for croissant,35202,0.0717718727693528,0.0269653233323904,0.0189198390378676,0.124623906500838,0.00778716207003422
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20649.Liking for cucumber,35202,-0.00094936030732834,0.0269835481034097,-0.0538371145900114,0.0519383939753547,0.971934492631417
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20650.Liking for curry,35202,-0.0589108605244027,0.0273008097713668,-0.112420447676282,-0.00540127337252386,0.0309609846880809
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20651.Liking for dairy products,35202,0.0765754350939545,0.0273666211002487,0.0229368577374671,0.130214012450442,0.00514857709858672
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20652.Liking for dark chocolate,35202,-0.00281979619565082,0.0271702800710837,-0.0560735451349749,0.0504339527436733,0.917343890032137
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20653.Liking for diet fizzy drinks,35202,0.134327407355653,0.0274622430964333,0.0805014108866438,0.188153403824662,1.01523487910321e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20654.Liking for dried fruit,35202,0.0505976423722385,0.0270702191899283,-0.00245998724002099,0.103655271984498,0.0616311002499301
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20655.Liking for eggs,35202,-0.00813285622535661,0.0275596204450333,-0.0621497122976218,0.0458839998469086,0.76792255639375
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20656.Liking for exercising alone,35202,-0.0665539052211915,0.0268567338784151,-0.119193103622885,-0.0139147068194979,0.0132225451886955
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20657.Liking for exercising with others,35202,-0.0793367327037338,0.026826214996157,-0.131916114096202,-0.0267573513112661,0.00310852318736955
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20658.Liking for extra virgin olive oil,35202,-0.118041011215677,0.0273058826758257,-0.171560541260295,-0.0645214811710583,1.55296035739375e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20659.Liking for fatty foods,35202,-1.77719318537958e-05,0.0266655573606989,-0.0522822643588236,0.052246720495116,0.999468241522149
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20660.Liking for fresh tomatoes,35202,-0.0373969784923134,0.0287121444315978,-0.0936727815782451,0.0188788245936183,0.192779000864317
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20661.Liking for fried chicken,35202,0.0394830069784396,0.0268295748205721,-0.0131029596698816,0.0920689736267609,0.141150602447607
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20662.Liking for fried or battered fish,35202,0.0543756045768507,0.0270482448929605,0.00136104458664824,0.107390164567053,0.0444210697297927
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20663.Liking for fruit,35202,0.0402574349190575,0.0294670178893797,-0.0174979201441268,0.0980127899822417,0.171907616649831
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20664.Liking for garlic,35202,-0.100989198415941,0.0274534401224719,-0.154797941055986,-0.0471804557758964,0.000235638047504686
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20665.Liking for gherkins,35202,-0.107841101818344,0.0268373220232007,-0.160442252983818,-0.0552399506528709,5.89920126682254e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20666.Liking for globe artichoke,35202,-0.154830219238843,0.0269711882902368,-0.207693748287707,-0.101966690189978,9.67756160270918e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20667.Liking for goat's cheese,35202,-0.0798461643945953,0.0268152642808001,-0.132404082384964,-0.0272882464042272,0.00291092808043546
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20668.Liking for going to a cafe,35202,0.0382584437944854,0.0270888088779353,-0.0148356216062678,0.0913525091952385,0.157879119867339
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20669.Liking for going to the gym,35202,-0.0494225077589073,0.0265780350177725,-0.101515456393741,0.00267044087592689,0.0629787218748998
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20670.Liking for going to the pub,35202,-0.0864070037083669,0.0268547126821289,-0.13904224056534,-0.0337717668513942,0.00129643484678674
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20671.Liking for grapefruit,35202,-0.0313098509739166,0.0268723936927748,-0.0839797426117553,0.0213600406639221,0.243990613166279
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20672.Liking for green olives,35202,-0.102492590740083,0.0269569725582284,-0.155328256954211,-0.0496569245259553,0.000144238138194647
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20673.Liking for haddock,35202,-0.0247166572531025,0.0274462972148291,-0.0785113997941675,0.0290780852879625,0.367848813578298
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20674.Liking for ham,35202,0.0774206161846485,0.0270449707411107,0.0244124735320715,0.130428758837225,0.0042086826537275
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20675.Liking for hard cheese,35202,0.00310228725356056,0.0274908441626326,-0.0507797673051994,0.0569843418123205,0.910153048001151
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20676.Liking for herring,35202,-0.0521963319546705,0.0265483566197873,-0.104231110929454,-0.000161552979887361,0.0493131381180575
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20677.Liking for honey,35202,0.0677362323316874,0.026865280545907,0.0150802824617097,0.120392182201665,0.0117048220744438
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20678.Liking for horseradish or wasabi,35202,-0.0898545238416109,0.0268753132407804,-0.14253013779354,-0.0371789098896813,0.000830311083365324
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20679.Liking for ice cream,35202,0.142679058819886,0.0270015639162993,0.0897559935439395,0.195602124095833,1.28665483153329e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20680.Liking for jam,35202,0.122415746225083,0.0268645040318043,0.069761318322747,0.17507017412742,5.24857192268276e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20681.Liking for kiwi fruit,35202,0.00440016917169181,0.0271543987855264,-0.04882245244794,0.0576227907913236,0.871275202042409
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20682.Liking for lager,35202,-0.0830416350771618,0.0270216001518283,-0.136003971374745,-0.0300792987795784,0.00212309513989307
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20683.Liking for lamb,35202,-0.0318019904248863,0.0271467015505768,-0.085009525464017,0.0214055446142443,0.241427968212588
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20684.Liking for lemons,35202,-0.0746951651595663,0.0270093055988845,-0.12763340413338,-0.0217569261857527,0.00569215666226259
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20685.Liking for lentils or beans,35202,-0.0514185924338368,0.0270953742266309,-0.104525525918033,0.00168834105035979,0.0577624573536688
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20686.Liking for liver,35202,0.010904010495427,0.0269130466409473,-0.0418455609208296,0.0636535819116836,0.685369723400054
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20687.Liking for mackerel,35202,-0.0734395286377852,0.0268079253713886,-0.125983062365707,-0.0208959949098635,0.00616344299532413
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20688.Liking for marzipan,35202,0.0923797474949344,0.0267819763504775,0.0398870738479985,0.14487242114187,0.000564034347409515
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20689.Liking for mayonnaise,35202,-0.0291454021948247,0.0269107282643148,-0.0818904295928816,0.0235996252032323,0.278813594264295
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20690.Liking for melon,35202,0.0257921036043969,0.0279605012450642,-0.0290104788359289,0.0805946860447227,0.35631466988691
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20691.Liking for milk chocolate,35202,0.19455443796383,0.0272172693713296,0.141208589996024,0.247900285931636,9.33287251770178e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20692.Liking for mushrooms,35202,-0.0126719121261447,0.0277874499062053,-0.067135313942307,0.0417914896900177,0.648377108763885
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20694.Liking for orange juice,35202,0.0801867391304409,0.0269050915848919,0.0274527596240528,0.132920718636829,0.00288525069018603
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20695.Liking for oranges,35202,-0.000245731231862675,0.0273779094299077,-0.0539064337144817,0.0534149712507563,0.992838817776866
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20696.Liking for pasta,35202,0.00759432902847404,0.0273436826030439,-0.0459992888734921,0.0611879469304402,0.781219977353559
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20697.Liking for pears,35202,0.0173951435646575,0.0273937186168946,-0.036296544924456,0.0710868320537711,0.525438086102209
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20698.Liking for pizza,35202,0.011915483552419,0.0269721838979945,-0.0409499968876503,0.0647809639924883,0.658664564913585
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20699.Liking for plain yogurt,35202,-0.0683193084253069,0.0268379960137103,-0.120921780612179,-0.0157168362384347,0.0109215502394355
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20700.Liking for plums,35202,0.0475742933981541,0.0274636654834064,-0.00625449094932252,0.101403077745631,0.0832539420619
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20701.Liking for pollock,35202,-0.00189151104683586,0.0267914650491906,-0.0544027825432494,0.0506197604495777,0.943716357545078
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20702.Liking for pork chop,35202,0.0185838945519389,0.0268823796928157,-0.0341055696459798,0.0712733587498576,0.489388726893273
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20703.Liking for porridge,35202,0.0309467409496526,0.0272861369437801,-0.0225340874601564,0.0844275693594617,0.256753028862846
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20704.Liking for potato crisps,35202,0.0566878416471435,0.02695109529456,0.00386369486980582,0.109511988424481,0.0354563428295844
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20705.Liking for potatoes,35202,0.0630430642921122,0.0273543983818984,0.00942844346359129,0.116657685120633,0.0212026314987844
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20706.Liking for prawns,35202,-0.106491899295863,0.0272739134138699,-0.159948769587048,-0.0530350290046778,9.49547397877299e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20707.Liking for raw carrots,35202,-0.0239495713434598,0.0273050347854185,-0.0774674395228801,0.0295682968359604,0.380444445971098
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20708.Liking for red meat,35202,-0.024854124803991,0.0268131764765172,-0.0774079506979647,0.0276997010899826,0.353978995218549
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20709.Liking for red wine,35202,-0.179608156061719,0.0269607648221885,-0.232451255113208,-0.126765057010229,2.82954120553625e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20710.Liking for regular (non-diet) fizzy drinks,35202,0.143793236372834,0.0277991180886306,0.0893069649191177,0.19827950782655,2.34822109257366e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20711.Liking for roast chicken,35202,0.0584809551449145,0.0282818120429639,0.0030486035407053,0.113913306749124,0.0386820587085437
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20712.Liking for salad dressing,35202,-0.0148596439434712,0.0269075149299969,-0.067598373206265,0.0378790853193226,0.580788766097467
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20713.Liking for salad leaves,35202,-0.0491134719985067,0.0275301995317475,-0.103072663080732,0.00484571908371846,0.07445279698296
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20714.Liking for salami,35202,-0.0863603123778351,0.0269825402659498,-0.139246091299097,-0.0334745334565735,0.00137519976357411
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20715.Liking for salmon,35202,-0.0610102893536655,0.0280040269856972,-0.115898182245632,-0.00612239646169903,0.0293800292132872
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20716.Liking for salty foods,35202,-0.00814012956634794,0.0266123691860633,-0.0603003731710321,0.0440201140383362,0.759703404195813
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20717.Liking for salty pretzels,35202,-0.0496416281320819,0.0269880987443374,-0.102538301670983,0.00325504540681936,0.0658840446039504
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20718.Liking for sardines,35202,-0.0614291642154116,0.0266446083101599,-0.113652596503325,-0.00920573192749825,0.0211565150695875
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20719.Liking for sausages (meat),35202,0.0197077521347993,0.0269319722225876,-0.0330789134214724,0.072494417691071,0.464329923086585
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20720.Liking for savoury biscuits,35202,0.0150852853119799,0.0269749403970326,-0.0377855978662041,0.0679561684901639,0.576013550730874
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20721.Liking for shellfish (other than prawns),35202,-0.131080480755642,0.0267424411314631,-0.18349566537331,-0.0786652961379745,9.63810115957471e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20722.Liking for skimmed milk,35202,0.0591544936044186,0.0269739332701951,0.00628558439483628,0.112023402814001,0.0283258709530649
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20723.Liking for smoked fish,35202,-0.0465907042901177,0.0268397255716371,-0.0991965664105263,0.00601515783029102,0.0826111695793407
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20724.Liking for soft cheese,35202,0.05735549752671,0.0269332712448774,0.00456628588675035,0.11014470916667,0.0332310395718316
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20725.Liking for soy sauce,35202,0.00621800836606753,0.0270539948663458,-0.0468078215719702,0.0592438383041053,0.818222599106003
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20726.Liking for soya milk,35202,-0.0431617235442738,0.0270517495595759,-0.0961831526810425,0.00985970559249483,0.110622925678263
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20727.Liking for spicy foods,35202,-0.109053036544247,0.0271377196026532,-0.162242966965447,-0.0558631061230469,5.89474556861806e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20728.Liking for spinach,35202,-0.0990155077521146,0.0271608030396594,-0.152250681709847,-0.0457803337943822,0.000268036110325621
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20729.Liking for spirits,35202,-0.0430532070344326,0.0270268152215042,-0.0960257648685808,0.00991935079971554,0.111192309136062
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20730.Liking for strawberries,35202,0.0888969240581009,0.0294863815776936,0.0311036161658213,0.14669023195038,0.00257678179051801
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20731.Liking for sweet coffee house drinks,35202,0.10856392165252,0.0275243450246965,0.0546162054041144,0.162511637900925,8.05198248420843e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20732.Liking for sweet foods,35202,0.238127923892953,0.0269713364999193,0.185264104353111,0.290991743432795,1.21183453990207e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20733.Liking for taking the stairs,35202,-0.0550105016026921,0.0275561782697531,-0.109020611011408,-0.00100039219397596,0.0459247544476721
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20734.Liking for tea with sugar,35202,0.115590921034258,0.0319358761386437,0.0529966038025163,0.178185238265999,0.000296494043410658
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20735.Liking for tea without sugar,35202,-0.0187238840473299,0.0281082764322493,-0.0738161058545384,0.0363683377598786,0.505338889360701
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20736.Liking for tomato ketchup,35202,0.0813183445345808,0.0269786373881262,0.0284402152538535,0.134196473815308,0.00258248718893175
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20737.Liking for tinned tuna,35202,0.0328068416179476,0.0271079532672386,-0.02032474678584,0.0859384300217353,0.226216126111971
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20738.Liking for turnip (white),35202,-0.0186084799462907,0.0268875636915283,-0.0713081047816861,0.0340911448891046,0.488898119823611
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20739.Liking for vegetables,35202,-0.0384593748895247,0.0296462587274429,-0.0965660419953129,0.0196472922162634,0.194562704942901
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20740.Liking for vinegar,35202,0.0288770803936071,0.0270289292422108,-0.024099620921126,0.0818537817083403,0.285373342753272
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20741.Liking for watching television,35202,0.0805593585202142,0.027129851985178,0.0273848486292653,0.133733868411163,0.00299007620105071
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20742.Liking for whisky,35202,-0.0986196999996856,0.0283595591659521,-0.154204435964952,-0.0430349640344194,0.000508055996301278
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20743.Liking for white bread,35202,0.0737133060950651,0.0268045356517898,0.0211764162175571,0.126250195972573,0.00596841118979204
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20744.Liking for white rice,35202,0.0199065905989514,0.0270516121111453,-0.0331145691388935,0.0729277503367963,0.46182232791525
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20745.Liking for white wine,35202,-0.131563893905918,0.0267565745124653,-0.18400677995035,-0.0791210078614859,8.90820144610118e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20746.Liking for whole grain breakfast cereal,35202,0.0717669712342705,0.0271258987640191,0.0186002096567931,0.124933732811748,0.00816347901382113
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20747.Liking for whole milk,35202,0.0610588821336235,0.0268032817050805,0.00852444999166572,0.113593314275581,0.0227428726817173
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20748.Liking for wholemeal bread,35202,0.0672637839737218,0.0280972133971325,0.0121932457153422,0.122334322232101,0.0166834324869101
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X20749.Liking for working up a sweat,35202,-0.100127381267932,0.0269419386975184,-0.152933581115068,-0.0473211814207961,0.000203043148060109
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X21001.Body mass index (BMI),51541,0.11355968108737,0.015806626396841,0.082578693349562,0.144540668825179,6.92549608136188e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X21002.Weight,51561,-0.0175528682109409,0.00917559159154558,-0.0355370277303703,0.000431291308488391,0.0557588884371434
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X21021.Pulse wave Arterial Stiffness index,32853,0.0138169010394936,0.00730128037796518,-0.000493608501318139,0.0281274105803054,0.0584705584506783
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21025.Frequency of discomfort or pain in abdomen in last 3 months,34566,0.031889703903016,0.0286726938375283,-0.0243087760185394,0.0880881838245714,0.266078145310347
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21033.Frequency of hard or lumpy stools in the last 3 months,34566,-0.0309660669440682,0.0297600201029954,-0.0892957063459391,0.0273635724578028,0.298119215538621
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21034.Frequency of loose or mushy or watery stools in the last 3 months,34566,-0.0221600240208139,0.0293040069541809,-0.0795958776510084,0.0352758296093807,0.449539104513116
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21040.Satisfaction with bowel habits,34536,0.0341510346596087,0.0276127566159271,-0.0199699683076083,0.0882720376268258,0.216194255465915
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21041.Degree to which abdominal pain or discomfort or altered bowel habits affect or interfere with life in general,34535,0.0377237885095875,0.0288629549076312,-0.0188476031093697,0.0942951801285448,0.191241989006867
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21042.Greatest number of times bowels opened per day,34525,0.00682267653066423,0.0296903423570821,-0.0513703944892166,0.0650157475505451,0.818255888215013
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21043.Least number of times bowels opened per week,34469,-0.0602249425148945,0.0292465809033815,-0.117548241085522,-0.00290164394426688,0.0394981818145872
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21044.Average number of times bowels opened per day,34499,0.00946013392180242,0.0327416137409445,-0.0547134290104489,0.0736336968540537,0.772638254564081
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21048.Degree bothered by back pain in the past 3 months,34571,-0.0335558311161353,0.0298656474881084,-0.0920925001928277,0.024980837960557,0.261225141198803
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21049.Degree bothered by pain in arms or legs or joints in the past 3 months,34566,-0.0294524505191136,0.0300394889208232,-0.0883298488039271,0.0294249477656998,0.326882359184267
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21050.Degree bothered by menstrual cramps or other problems with period in the last 3 months,30120,0.0534525488556072,0.0448045769406535,-0.0343644219480736,0.141269519659288,0.232908575783336
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21051.Degree bothered by headaches in the last 3 months,34568,-0.0205152916740071,0.0314065319438155,-0.0820720942838856,0.0410415109358714,0.513630190492125
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21052.Degree bothered by chest pain in the last 3 months,34566,-0.0657647092094139,0.0444573728144064,-0.15290115992565,0.0213717415068227,0.139096081966699
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21053.Degree bothered by dizziness in the last 3 months,34569,-0.0487974840594669,0.0353878749255077,-0.118157718913462,0.0205627507945282,0.167944427808116
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21054.Degree bothered by fainting spells in the last 3 months,34568,0.0288159917310051,0.0883443641742906,-0.144338962050604,0.201970945512615,0.744296028438245
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21055.Degree bothered by feeling heart pound or race in the last 3 months,34569,0.0378350010430387,0.0338824863547011,-0.0285746722121754,0.104244674298253,0.264167511172116
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21056.Degree bothered by shortness of breath in the last 3 months,34570,-0.06270326080478,0.0347753343579742,-0.130862916146409,0.00545639453684936,0.0714012623700697
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21057.Degree bothered by pain or problems during intercourse in the last 3 months,34323,0.0293821529475361,0.0310753719515522,-0.0315255760775062,0.0902898819725784,0.344419124971156
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21058.Degree bothered by urinary frequency or bladder irritability in the last 3 months,34569,-0.0161676446138557,0.0309333808509704,-0.0767970710817576,0.0444617818540463,0.601221606897272
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21059.Degree bothered by nausea in the last 3 months,34571,-0.122372347862866,0.0418467669712582,-0.204392011126532,-0.0403526845992,0.00345959468978273
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21060.Degree bothered by feeling tired all the time in the last 3 months,34568,-0.12013992080466,0.0298835912503958,-0.178711759655436,-0.0615680819538846,5.85315319224346e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X21061.Degree bothered by trouble sleeping in the last 3 months,34566,-0.0605147251286335,0.0297761821784544,-0.118876042198404,-0.00215340805886292,0.0421459251749049
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X21100.Water hardness (USGS classification),51311,-0.0336820147131552,0.0183648462809746,-0.0696771134238655,0.00231308399755507,0.0666576472237782
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2139.Age first had sexual intercourse,48639,-0.00613917119059459,0.00421018772644132,-0.0143911391344196,0.0021127967532304,0.144806249909904
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2149.Lifetime number of sexual partners,46664,-0.0476913258652761,0.0209311543619905,-0.0887163884147775,-0.00666626331577459,0.0227068893449908
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22032.IPAQ activity group,46648,-0.144367254953964,0.0201755663240403,-0.183911364949083,-0.104823144958845,8.5862290625664e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22033.Summed days activity,47217,-0.0314552730007577,0.00403735015683039,-0.0393684793081453,-0.0235420666933701,6.92018602877312e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22034.Summed minutes activity,46648,-0.0279445366869057,0.00412063820152768,-0.0360209875619,-0.0198680858119114,1.2175660618909e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22037.MET minutes per week for walking,45884,-0.01835558472406,0.00404989322039876,-0.0262933754360416,-0.0104177940120784,5.86343438381568e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22038.MET minutes per week for moderate activity,46648,-0.0232088393051045,0.00422280967514853,-0.0314855462683956,-0.0149321323418134,3.92518012683855e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22039.MET minutes per week for vigorous activity,46648,-0.163917278304253,0.0202556438463773,-0.203618340243152,-0.124216216365353,6.13880309245163e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X22040.Summed MET minutes per week for all activity,45884,-0.0304838402886448,0.00417038557228109,-0.0386577960103157,-0.0223098845669739,2.77086943591072e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X2217.Age started wearing glasses or contact lenses,45997,-0.0113453530436235,0.00487835970961177,-0.0209069380744626,-0.00178376801278446,0.0200462633360857
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X22501.Year ended full time education,31250,-0.0493348285126162,0.0204996338531679,-0.0895141108648252,-0.00915554616040714,0.0161252958635017
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X22506.Tobacco smoking,31200,-0.121653433073823,0.0716596354276067,-0.262106318511932,0.0187994523642865,0.0896150477882174
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2277.Frequency of solarium or sunlamp use,49658,0.0194099046103595,0.0402225511175049,-0.0594262955799502,0.0982461048006692,0.629410332755544
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23098.Weight,51191,-0.016918249456097,0.00924582169487894,-0.0350400599780597,0.00120356106586569,0.0672867748424056
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23099.Body fat percentage,51169,0.0554417626427074,0.00895692108871901,0.0378861973088182,0.0729973279765967,6.10879912646914e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23100.Whole body fat mass,51136,0.0341039054748833,0.00851997434728588,0.017404755754203,0.0508030551955636,6.27579315770574e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23101.Whole body fat-free mass,51186,-0.0450232194688234,0.00788625109177221,-0.060480271608697,-0.0295661673289499,1.14766131502049e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23102.Whole body water mass,51191,-0.0449168006454437,0.00788649205730716,-0.0603743250777657,-0.0294592762131216,1.24338408257715e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23104.Body mass index (BMI),51191,0.114639175413797,0.0159285869533019,0.0834191449853257,0.145859205842269,6.31053630991775e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23105.Basal metabolic rate,51189,-0.0454412404244062,0.00845419052706127,-0.0620114538574463,-0.0288710269913661,7.7211173715367e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23106.Impedance of whole body,51188,0.031767815253024,0.00648421634748515,0.0190587512119531,0.0444768792940949,9.67516620971593e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23107.Impedance of leg (right),51188,0.0336525071641253,0.00534772696601535,0.0231709623107352,0.0441340520175154,3.1639116993643e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23108.Impedance of leg (left),51187,0.0296104554877652,0.00531021134065752,0.0192024412600765,0.040018469715454,2.48243441800421e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23109.Impedance of arm (right),51181,0.0191053740079058,0.00650396141659875,0.00635760963137222,0.0318531383844393,0.00331148490310092
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23110.Impedance of arm (left),51186,0.0138256090233161,0.0064952508290386,0.00109491739840045,0.0265563006482318,0.033298606946352
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23111.Leg fat percentage (right),51187,0.0735711677632975,0.0110732105172886,0.0518676751494117,0.0952746603771832,3.10871943084727e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23112.Leg fat mass (right),51186,0.0445619828125971,0.0115081654612813,0.0220059785084856,0.0671179871167085,0.000108105905990125
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23113.Leg fat-free mass (right),51186,-0.0582232913354214,0.00848556625450068,-0.0748550011942427,-0.0415915814766,6.96190081206229e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23114.Leg predicted mass (right),51185,-0.0585574267320844,0.00851832693489206,-0.0752533475244728,-0.0418615059396959,6.36394557570569e-12
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23115.Leg fat percentage (left),51184,0.0692179258241805,0.0114697718289879,0.0467371730393643,0.0916986786089968,1.61194514107777e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23116.Leg fat mass (left),51184,0.0381145754949645,0.0119700002142999,0.0146533750749368,0.0615757759149922,0.00145330024008343
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23117.Leg fat-free mass (left),51182,-0.0542986066377567,0.00880504377130534,-0.0715564924295151,-0.0370407208459982,7.06789201223467e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23118.Leg predicted mass (left),51181,-0.0535101742231322,0.00883773242586219,-0.0708321297778221,-0.0361882186684423,1.42477573024189e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23119.Arm fat percentage (right),51181,0.0605831521888157,0.00986917525834204,0.0412395686824653,0.0799267356951661,8.43846578542562e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23120.Arm fat mass (right),51178,0.0496978512546084,0.00966236521618648,0.0307596154308829,0.0686360870783339,2.7160618907776e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23121.Arm fat-free mass (right),51178,-0.0351243274231828,0.00789463084513813,-0.0505978038796536,-0.0196508509667121,8.6554663501696e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23122.Arm predicted mass (right),51177,-0.0326698592118371,0.00790069136421911,-0.0481552142857065,-0.0171845041379676,3.559162527607e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23123.Arm fat percentage (left),51173,0.0543829809880405,0.0100891416142068,0.0346082634241952,0.0741576985518858,7.09428814648015e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23124.Arm fat mass (left),51172,0.0431882959159193,0.0096247293219988,0.0243238264448016,0.0620527653870369,7.24522869040943e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23125.Arm fat-free mass (left),51168,-0.0305364663042557,0.00802612020392228,-0.0462676619039434,-0.0148052707045681,0.000142322297516803
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23126.Arm predicted mass (left),51167,-0.0286208423180187,0.00806425169154721,-0.0444267756334513,-0.0128149090025862,0.000387197921288659
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23127.Trunk fat percentage,51164,0.0340002886513631,0.00641959552644036,0.02141788141954,0.0465826958831862,1.19068027306194e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23128.Trunk fat mass,51161,0.024171841931006,0.00700209095288324,0.0104477436633548,0.0378959401986571,0.000557106197831699
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23129.Trunk fat-free mass,51155,-0.036396757045461,0.00717807149213353,-0.0504657771700427,-0.0223277369208793,3.99264102171599e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X23130.Trunk predicted mass,51153,-0.0361317038339842,0.00716683915293284,-0.0501787085737325,-0.0220846990942358,4.64821001077963e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23400.Total Cholesterol,39585,-0.0481472802040806,0.00528704213102128,-0.0585098827808823,-0.0377846776272789,9.49876497756878e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23401.Total Cholesterol Minus HDL-C,39585,0.0181346136671556,0.00514981902346632,0.00804096838116164,0.0282282589531496,0.000430477348531131
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,"X23402.Remnant Cholesterol (Non-HDL, Non-LDL -Cholesterol)",39585,0.0376349084580198,0.00516369259213497,0.0275140709774353,0.0477557459386044,3.28635194189905e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23403.VLDL Cholesterol,39585,0.0976931140154223,0.00504326539405849,0.0878083138430676,0.107577914187777,1.2425405709127e-82
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23404.Clinical LDL Cholesterol,39585,-0.00361676406963187,0.00514676388912917,-0.0137044212923251,0.00647089315306131,0.482237012369072
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23405.LDL Cholesterol,39585,-0.000185615644298488,0.00510568324195355,-0.0101927547985274,0.00982152350993046,0.970999986261147
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23406.HDL Cholesterol,39585,-0.227745031223345,0.00553765797744259,-0.238598840859132,-0.216891221587557,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23407.Total Triglycerides,39585,0.131974035513551,0.00512350163992811,0.121931972299292,0.14201609872781,2.38844068584623e-143
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23408.Triglycerides in VLDL,39585,0.144314281411289,0.00519108907806013,0.134139746818291,0.154488816004287,4.33350431512595e-166
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23409.Triglycerides in LDL,39585,0.0816201473585444,0.00494979824948643,0.071918542789551,0.0913217519275378,1.40526756634932e-60
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23410.Triglycerides in HDL,39585,0.0621582853173075,0.0049009610849152,0.0525524015908737,0.0717641690437413,1.11278196281441e-36
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23411.Total Phospholipids in Lipoprotein Particles,39585,-0.0579941136716072,0.00522876245020138,-0.0682424880740019,-0.0477457392692124,1.7620789147257e-28
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23412.Phospholipids in VLDL,39585,0.12456199876545,0.00506225938870348,0.114639970363591,0.134484027167309,3.26018718159896e-131
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23413.Phospholipids in LDL,39585,0.0105521309716407,0.00511094325708404,0.000534682187755972,0.0205695797555254,0.0389757849180223
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23414.Phospholipids in HDL,39585,-0.170220053700803,0.00530420486056932,-0.180616295227519,-0.159823812174087,6.23096224242251e-219
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23415.Total Esterified Cholesterol,39585,-0.0607824889781497,0.00529788919504921,-0.0711663518004462,-0.0503986261558533,2.38201407553535e-30
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23416.Cholesteryl Esters in VLDL,39585,0.0841568915735634,0.00505764528204194,0.0742439068207612,0.0940698763263656,1.21255793021899e-61
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23417.Cholesteryl Esters in LDL,39585,0.00980432935649559,0.00508703337253859,-0.000166256053680034,0.0197749147666712,0.053958043908457
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23418.Cholesteryl Esters in HDL,39585,-0.233804311795353,0.00551063762250242,-0.244605161535458,-0.223003462055248,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23419.Total Free Cholesterol,39585,-0.016128268222863,0.00524819483133447,-0.0264147300922786,-0.00584180635344747,0.00212204391237756
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23420.Free Cholesterol in VLDL,39585,0.114027617042096,0.00505238459944103,0.104124943227192,0.123930290857,5.0276339148425e-111
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23421.Free Cholesterol in LDL,39585,-0.0274495056324376,0.00516005110108668,-0.0375632057905675,-0.0173358054743077,1.05408939228376e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23422.Free Cholesterol in HDL,39585,-0.19218411014874,0.00556818293315987,-0.203097748697733,-0.181270471599747,1.07077459600853e-251
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23423.Total Lipids in Lipoprotein Particles,39585,-0.00173011761563359,0.0051186325416785,-0.0117626373973234,0.00830240216605626,0.73536478242629
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23424.Total Lipids in VLDL,39585,0.132207228582451,0.00509962141069292,0.122211970617493,0.142202486547409,3.84220042018451e-145
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23425.Total Lipids in LDL,39585,0.00804869154447534,0.0051004254617343,-0.00194814236052388,0.0180455254494746,0.11457580805807
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23426.Total Lipids in HDL,39585,-0.189310361281403,0.00538662604558091,-0.199868148330741,-0.178752574232064,1.5061196173133e-260
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23427.Total Concentration of Lipoprotein Particles,39585,-0.147830048294521,0.00513590541588324,-0.157896422909652,-0.13776367367939,1.33830715661972e-177
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23428.Concentration of VLDL Particles,39585,0.104547172104592,0.00502346375373537,0.0947011831472707,0.114393161061913,6.4207663398327e-95
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23429.Concentration of LDL Particles,39585,0.0476304170100543,0.00509910568220002,0.0376361698729422,0.0576246641471663,1.0802128312926e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23430.Concentration of HDL Particles,39585,-0.162936358064546,0.00510860348464144,-0.172949220894443,-0.152923495234648,2.33006341440181e-216
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23431.Average Diameter for VLDL Particles,39585,0.159229131684785,0.00544658521669786,0.148553824660057,0.169904438709513,5.32697999985565e-183
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23432.Average Diameter for LDL Particles,39585,-0.0565498485754031,0.00506868308389191,-0.0664844674198312,-0.046615229730975,8.51707107303324e-29
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23433.Average Diameter for HDL Particles,39585,-0.174157400350903,0.00575685674341806,-0.185440839568002,-0.162873961133803,1.85893022724006e-195
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23434.Phosphoglycerides,39573,-0.0740460737730508,0.00515787496392569,-0.0841555087023452,-0.0639366388437565,1.92376097951267e-46
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23435.Triglycerides to Phosphoglycerides ratio,39573,0.20150025648572,0.00536999906780553,0.190975058312822,0.212025454658619,3.41969582885385e-295
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23436.Total Cholines,39573,-0.0861762438210812,0.00523411016450194,-0.0964350997435049,-0.0759173878986574,2.11989114172775e-60
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23437.Phosphatidylcholines,39573,-0.0912524601826653,0.00521505148393958,-0.101473961091187,-0.0810309592741437,6.54321197204221e-68
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23438.Sphingomyelins,39572,-0.0864742146095627,0.0053988804309834,-0.0970560202542902,-0.0758924089648352,2.75913420922783e-57
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23439.Apolipoprotein B,39585,0.0502270932473578,0.00511463168688935,0.0402024151410547,0.0602517713536609,1.07026799076811e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23440.Apolipoprotein A1,39585,-0.179404911668484,0.00524410824210741,-0.189683363823015,-0.169126459513953,1.78740002449567e-247
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23441.Apolipoprotein B to Apolipoprotein A1 ratio,39585,0.136760873899961,0.00502194253317025,0.126917866534947,0.146603881264975,1.31252414013615e-159
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23442.Total Fatty Acids,39573,0.0389714303312964,0.00498036716323453,0.0292099106913567,0.0487329499712361,5.39769342654034e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23443.Degree of Unsaturation,39573,-0.126312627346624,0.00543778563012778,-0.136970687181675,-0.115654567511574,2.20130843722721e-117
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23444.Omega-3 Fatty Acids,39573,-0.0172789302760056,0.00506647442396314,-0.0272092201469733,-0.00734864040503783,0.000650201957780342
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23445.Omega-6 Fatty Acids,39573,-0.0111593500779911,0.00506230666963216,-0.0210814711504701,-0.00123722900551208,0.0275106490744126
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23446.Polyunsaturated Fatty Acids,39573,-0.0138887803788004,0.00506233055705478,-0.0238109482706278,-0.00396661248697306,0.00608468591886692
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23447.Monounsaturated Fatty Acids,39573,0.0864262734434976,0.00503111218630948,0.076565293558331,0.0962872533286642,1.52933084550629e-65
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23448.Saturated Fatty Acids,39573,0.0400721602018904,0.00500732927132687,0.0302577948300897,0.0498865255736911,1.30166586838885e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23449.Linoleic Acid,39573,-2.41303476235604e-05,0.00509962180918854,-0.0100193890936331,0.00997112839838597,0.996224650697125
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23450.Docosahexaenoic Acid,39573,-0.0897604976337204,0.00524786107197264,-0.100046305334787,-0.079474689932654,5.34876198341141e-65
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23451.Omega-3 Fatty Acids to Total Fatty Acids percentage,39573,-0.0459262616131023,0.00511819027432551,-0.0559579145507803,-0.0358946086754243,3.20178631221591e-19
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23452.Omega-6 Fatty Acids to Total Fatty Acids percentage,39573,-0.103975759316175,0.00516039641221816,-0.114090136284122,-0.0938613823482269,3.67831776957842e-89
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23453.Polyunsaturated Fatty Acids to Total Fatty Acids percentage,39573,-0.130145225260437,0.00533819700226215,-0.140608091384871,-0.119682359136004,6.83360238501003e-129
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23454.Monounsaturated Fatty Acids to Total Fatty Acids percentage,39573,0.169657447466905,0.00538589367132516,0.159101095871108,0.180213799062702,3.00230539743634e-211
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23455.Saturated Fatty Acids to Total Fatty Acids percentage,39573,0.0240075405961785,0.00499921086058117,0.0142090873094394,0.0338059938829176,1.58326079432034e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23456.Linoleic Acid to Total Fatty Acids percentage,39573,-0.0723567875428327,0.00531921969390188,-0.0827824581428804,-0.061931116942785,6.6468931576531e-42
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23457.Docosahexaenoic Acid to Total Fatty Acids percentage,39573,-0.118973843281405,0.0052851538532091,-0.129332744833695,-0.108614941729115,1.7982599657893e-110
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23458.Polyunsaturated Fatty Acids to Monounsaturated Fatty Acids ratio,39573,-0.161617318073705,0.00539975471473268,-0.172200837314581,-0.151033798832829,1.78858857742763e-191
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23459.Omega-6 Fatty Acids to Omega-3 Fatty Acids ratio,39571,0.01509212061745,0.00508771578600922,0.00512019767687195,0.0250640435580281,0.00301777059471402
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23460.Alanine,39581,0.00891807295885565,0.00493800267940652,-0.000760412292781138,0.0185965582104924,0.0709361883817387
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23461.Glutamine,39537,-0.0510728732226804,0.00485726520051538,-0.0605931130156906,-0.0415526334296703,9.00198896028936e-26
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23462.Glycine,39566,-0.000719119937724274,0.00512560135898558,-0.010765298601336,0.00932705872588746,0.888425061386501
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23463.Histidine,39567,-0.0019703054816377,0.00488009913757343,-0.0115352997912816,0.00759468882800622,0.686407269984314
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23464.Total Concentration of Branched-Chain Amino Acids (Leucine + Isoleucine + Valine),39575,0.0519951514082829,0.00518942778389406,0.0418238729518505,0.0621664298647152,1.47352321838845e-23
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23465.Isoleucine,39583,0.0591216435337629,0.00505972372303292,0.0492045850366183,0.0690387020309074,2.05668866943801e-31
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23466.Leucine,39584,0.0423426688364345,0.00523070596897587,0.0320904851372418,0.0525948525356272,6.14156100280438e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23467.Valine,39575,0.0496058262264315,0.00516629151313046,0.0394798948606958,0.0597317575921672,9.01278178076188e-22
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23468.Phenylalanine,39581,0.0306807014216113,0.00491923169226677,0.0210390073047684,0.0403223955384541,4.57770522593721e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23469.Tyrosine,39568,0.0202466801308135,0.00501926380806642,0.0104089230670033,0.0300844371946237,5.51428071888354e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23470.Glucose,39557,0.00711027668473181,0.00502344318071227,-0.00273567194946424,0.0169562253189279,0.156965535084812
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23471.Lactate,39556,-0.00358880602060601,0.0049396542166053,-0.0132705282851524,0.00609291624394037,0.467524876262499
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23472.Pyruvate,39533,-0.0424470702399891,0.00485741422592117,-0.0519676021227946,-0.0329265383571836,2.59538840096169e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23473.Citrate,39583,0.0069146918574753,0.00500290538467509,-0.00289100269648787,0.0167203864114385,0.166949812549408
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23474.3-Hydroxybutyrate,39339,-0.000409449956983267,0.00485361243342804,-0.00992253032650222,0.00910363041253569,0.932771429263686
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23475.Acetate,39571,-0.023197893073243,0.00492893940344026,-0.0328586143039859,-0.0135371718425001,2.54195918003991e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23476.Acetoacetate,39585,0.0228475744840832,0.00483809712872565,0.0133649041117809,0.0323302448563854,2.35055430421871e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23477.Acetone,39585,-0.0483359043059789,0.00485500061134794,-0.0578517055042209,-0.038820103107737,2.7852693127728e-23
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23478.Creatinine,39161,0.0489743098749258,0.00609484610188389,0.0370284115152333,0.0609202082346182,1.00067716993031e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23479.Albumin,39584,-0.0749088603613773,0.00497928360949745,-0.0846682562359923,-0.0651494644867623,8.51616812268646e-51
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23480.Glycoprotein Acetyls,39585,0.151702838810474,0.00512689654015105,0.141654121591778,0.16175155602917,2.6558505557664e-187
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23481.Concentration of Chylomicrons and Extremely Large VLDL Particles,39585,0.151233764725111,0.00514030290430116,0.141158771032681,0.161308758417542,2.96177550381161e-185
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23482.Total Lipids in Chylomicrons and Extremely Large VLDL,39585,0.147556598859013,0.00517099842980318,0.137421441936599,0.157691755781427,1.16489850663893e-174
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23483.Phospholipids in Chylomicrons and Extremely Large VLDL,39585,0.154876002268173,0.00516504437435296,0.144752515294441,0.164999489241905,3.7309633875071e-192
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23484.Cholesterol in Chylomicrons and Extremely Large VLDL,39585,0.147953289178258,0.00513903492038724,0.137880780734299,0.158025797622217,1.12157043751854e-177
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23485.Cholesteryl Esters in Chylomicrons and Extremely Large VLDL,39585,0.147560608774228,0.00516462043704708,0.137437952717616,0.15768326483084,4.37687616256871e-175
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23486.Free Cholesterol in Chylomicrons and Extremely Large VLDL,39585,0.142614969890083,0.00510054265359017,0.132617906289047,0.15261203349112,6.0848384500435e-168
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23487.Triglycerides in Chylomicrons and Extremely Large VLDL,39585,0.142655339913767,0.00516889123880233,0.132524313085714,0.152786366741819,8.94833215874949e-164
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23488.Concentration of Very Large VLDL Particles,39585,0.161466519037075,0.0052306050349957,0.151214533168484,0.171718504905667,3.35786840305512e-203
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23489.Total Lipids in Very Large VLDL,39585,0.161554359110549,0.00523551505008528,0.151292749612382,0.171815968608716,4.78702532819729e-203
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23490.Phospholipids in Very Large VLDL,39585,0.162412539045535,0.00519537049874496,0.152229612867995,0.172595465223075,3.50865238666669e-208
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23491.Cholesterol in Very Large VLDL,39585,0.149101037716804,0.00514235270686994,0.139022026411339,0.159180049022269,4.06263293830902e-180
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23492.Cholesteryl Esters in Very Large VLDL,39585,0.137257793586,0.00511402430767458,0.127234305942958,0.147281281229042,3.43226444199598e-155
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23493.Free Cholesterol in Very Large VLDL,39585,0.157158580021949,0.00516459563571322,0.147035972575952,0.167281187467947,1.13067556744594e-197
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23494.Triglycerides in Very Large VLDL,39585,0.1609817992749,0.00528510538052413,0.150622992729073,0.171340605820728,4.83207973734119e-198
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23495.Concentration of Large VLDL Particles,39585,0.150975055664728,0.00519168245468224,0.14079935805355,0.161150753275905,3.84276805288207e-181
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23496.Total Lipids in Large VLDL,39585,0.148808078103972,0.00520185184853574,0.138612448480842,0.159003707727103,1.67425160452078e-175
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23497.Phospholipids in Large VLDL,39585,0.157184794207698,0.00521207761114729,0.14696912208985,0.167400466325547,2.75785772060223e-194
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23498.Cholesterol in Large VLDL,39585,0.142318406977013,0.00511786031387467,0.132287400761819,0.152349413192207,3.52340901457569e-166
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23499.Cholesteryl Esters in Large VLDL,39585,0.129039318374823,0.00505211579480511,0.119137171417005,0.138941465332641,5.02390012453355e-141
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23500.Free Cholesterol in Large VLDL,39585,0.153697683729278,0.00519711183975056,0.143511344523367,0.163884022935189,4.15250339550943e-187
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23501.Triglycerides in Large VLDL,39585,0.142311455949765,0.00524353320795507,0.132034130862173,0.152588781037357,1.44627497182796e-158
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23502.Concentration of Medium VLDL Particles,39585,0.0877991172722931,0.00504865509798785,0.0779037532802369,0.0976944812643493,4.12502576270649e-67
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23503.Total Lipids in Medium VLDL,39585,0.0982089225871215,0.00505726173790269,0.0882966895808322,0.108121155593411,4.95722830688421e-83
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23504.Phospholipids in Medium VLDL,39585,0.0835698149713725,0.00505159238637105,0.0736686938940852,0.0934709360486598,5.86090993135449e-61
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23505.Cholesterol in Medium VLDL,39585,0.0395466188639127,0.0051310519063762,0.0294897571274154,0.0496034806004101,1.36145171526944e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23506.Cholesteryl Esters in Medium VLDL,39585,0.0133059790063925,0.00519683976802853,0.0031201730610566,0.0234917849517284,0.0104644856548498
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23507.Free Cholesterol in Medium VLDL,39585,0.0703035373328804,0.00506159371279109,0.0603828136558099,0.0802242610099509,1.32517120473009e-43
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23508.Triglycerides in Medium VLDL,39585,0.124299194327429,0.00515192649438673,0.114201418398431,0.134396970256427,2.56217679362539e-126
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23509.Concentration of Small VLDL Particles,39585,0.115948601209614,0.00503431037393295,0.106081352876705,0.125815849542523,1.81430879292008e-115
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23510.Total Lipids in Small VLDL,39585,0.110267294099034,0.00502925037458775,0.100409963364842,0.120124624833226,5.55424149373344e-105
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23511.Phospholipids in Small VLDL,39585,0.0877685721779403,0.00502490716436963,0.0779197541357758,0.0976173902201048,1.1179093674426e-67
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23512.Cholesterol in Small VLDL,39585,0.0868253202065653,0.0050358175835185,0.076955117742869,0.0966955226702615,5.2351559147704e-66
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23513.Cholesteryl Esters in Small VLDL,39585,0.0988701305943395,0.00503104357628074,0.0890092851848293,0.10873097600385,5.79871933167156e-85
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23514.Free Cholesterol in Small VLDL,39585,0.064303046292454,0.00505695118025777,0.0543914219791488,0.0742146706057593,7.34036368585387e-37
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23515.Triglycerides in Small VLDL,39585,0.121536954756617,0.00506975894458343,0.111600227225233,0.131473682288,9.13764865525804e-125
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23516.Concentration of Very Small VLDL Particles,39585,0.0624382269688213,0.00507877395618745,0.0524838300146939,0.0723926239229487,1.40695911299914e-34
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23517.Total Lipids in Very Small VLDL,39585,0.062552066815827,0.00506232970949175,0.0526299005852232,0.0724742330464308,6.53422838541002e-35
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23518.Phospholipids in Very Small VLDL,39585,0.0765092631396616,0.00501927341313752,0.0666714872499121,0.0863470390294111,4.31256459440725e-52
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23519.Cholesterol in Very Small VLDL,39585,0.0265329049984632,0.00527119461454777,0.0162013635539496,0.0368644464429769,4.86758613205931e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23520.Cholesteryl Esters in Very Small VLDL,39585,0.0123434385725124,0.00534359206296275,0.00186999812910544,0.0228168790159194,0.020903723201384
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23521.Free Cholesterol in Very Small VLDL,39585,0.0574850977569502,0.00510517867513915,0.0474789475536774,0.0674912479602229,2.67206129803254e-29
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23522.Triglycerides in Very Small VLDL,39585,0.102132687740827,0.00494331020692498,0.0924437997352542,0.1118215757464,1.36189637944533e-93
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23523.Concentration of IDL Particles,39585,0.0193354425673107,0.00523853696189588,0.00906791012199476,0.0296029750126266,0.000224128215660797
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23524.Total Lipids in IDL,39585,-0.0244632748510364,0.00535453163624962,-0.0349581568580857,-0.0139683928439872,4.94477401026236e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23525.Phospholipids in IDL,39585,-0.0129143273449057,0.00535494850564726,-0.0234100264159743,-0.0024186282738371,0.0158913656739898
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23526.Cholesterol in IDL,39585,-0.0402065612624219,0.00538147898110537,-0.0507542600653885,-0.0296588624594554,8.35857927520662e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23527.Cholesteryl Esters in IDL,39585,-0.0413972320810415,0.00537240177341291,-0.0519271395569308,-0.0308673246051522,1.38045774916426e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23528.Free Cholesterol in IDL,39585,-0.0355834612356133,0.00538405885733719,-0.0461362165959942,-0.0250307058752324,3.99258254313147e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23529.Triglycerides in IDL,39585,0.0787898416522775,0.00490178358614128,0.0691823458234406,0.0883973374811144,1.12341633261145e-57
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23530.Concentration of Large LDL Particles,39585,0.0384697517307907,0.00511028486098326,0.0284535934032635,0.0484859100583179,5.43509719429522e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23531.Total Lipids in Large LDL,39585,-0.0113567288405254,0.00513748066758715,-0.0214261909489962,-0.0012872667320546,0.0270803980726585
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23532.Phospholipids in Large LDL,39585,-0.00833374788933276,0.00515536548617215,-0.0184382642422302,0.00177076846356466,0.106002139909673
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23533.Cholesterol in Large LDL,39585,-0.0195963104423516,0.00514381514678906,-0.0296781881300581,-0.00951443275464499,0.00013967398204775
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23534.Cholesteryl Esters in Large LDL,39585,-0.0120939359083579,0.00511704599003523,-0.022123346048827,-0.00206452576788888,0.0181172511001886
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23535.Free Cholesterol in Large LDL,39585,-0.0400429173459713,0.00522081984711191,-0.0502757242463107,-0.029810110445632,1.82246039389159e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23536.Triglycerides in Large LDL,39585,0.071204396646259,0.00492977686479395,0.0615420339912629,0.0808667593012552,5.48713034819133e-47
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23537.Concentration of Medium LDL Particles,39585,0.0554504664192897,0.00507186661447012,0.0455096078549283,0.0653913249836511,1.00913516948373e-27
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23538.Total Lipids in Medium LDL,39585,0.0365568563907766,0.00505942991707441,0.0266403737533108,0.0464733390282424,5.22220530393344e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23539.Phospholipids in Medium LDL,39585,0.0329861951480954,0.00505230647323757,0.0230836744605497,0.042888715835641,6.82669783648687e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23540.Cholesterol in Medium LDL,39585,0.0318527442465791,0.00506249250991297,0.0219302589271497,0.0417752295660086,3.21882671150192e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23541.Cholesteryl Esters in Medium LDL,39585,0.046011578328326,0.00506371887495289,0.0360866893334183,0.0559364673232336,1.14220113238594e-19
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23542.Free Cholesterol in Medium LDL,39585,-0.00794480857334764,0.00506575898506229,-0.0178736961840697,0.00198407903737444,0.116823025729144
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23543.Triglycerides in Medium LDL,39585,0.0880570805870777,0.00498576801097978,0.0782849752855573,0.097829185888598,3.84582955166444e-69
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23544.Concentration of Small LDL Particles,39585,0.0648473768079096,0.0050859239019402,0.0548789659601068,0.0748157876557124,4.73411772871052e-37
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23545.Total Lipids in Small LDL,39585,0.0464162917555533,0.00508836739314232,0.0364430916649943,0.0563894918461122,8.24867145025607e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23546.Phospholipids in Small LDL,39585,0.0403395340917446,0.00509848995572374,0.030346493778526,0.0503325744049631,2.69936667654243e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23547.Cholesterol in Small LDL,39585,0.03736571769137,0.00508581688127728,0.0273975166040665,0.0473339187786734,2.12585267204029e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23548.Cholesteryl Esters in Small LDL,39585,0.050922631569689,0.00508065739743137,0.0409645430707235,0.0608807200686545,1.42378543903675e-23
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23549.Free Cholesterol in Small LDL,39585,-0.00167785302629539,0.00507886989446017,-0.0116324380194373,0.00827673196684656,0.741132724651377
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23550.Triglycerides in Small LDL,39585,0.114661703811827,0.00501841535328416,0.10482560971939,0.124497797904264,1.07368527151438e-113
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23551.Concentration of Very Large HDL Particles,39585,-0.125095767083575,0.00587180432279291,-0.136604503556249,-0.113587030610901,2.60172386533418e-99
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23552.Total Lipids in Very Large HDL,39585,-0.126714217134376,0.00589150089343068,-0.1382615588855,-0.115166875383252,3.74217287619386e-101
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23553.Phospholipids in Very Large HDL,39585,-0.12112923433588,0.0058320152510929,-0.132559984228022,-0.109698484443738,1.50694403548633e-94
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23554.Cholesterol in Very Large HDL,39585,-0.142819397544598,0.00595876579560609,-0.154498578503985,-0.13114021658521,1.02541366213913e-124
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23555.Cholesteryl Esters in Very Large HDL,39585,-0.161618472500024,0.0060031647869072,-0.173384675482362,-0.149852269517686,4.08319980107858e-156
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23556.Free Cholesterol in Very Large HDL,39585,-0.0747233305757872,0.00567604387816372,-0.0858483765769881,-0.0635982845745863,2.26333146967798e-39
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23557.Triglycerides in Very Large HDL,39585,0.0414296550246697,0.0048325281647617,0.0319578998217368,0.0509014102276027,1.10013166901785e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23558.Concentration of Large HDL Particles,39585,-0.214743013828299,0.00586262504757817,-0.226233758921552,-0.203252268735046,5.9522197950744e-282
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23559.Total Lipids in Large HDL,39585,-0.207513473169242,0.00578718490776575,-0.218856355588463,-0.196170590750021,9.86462913169536e-271
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23560.Phospholipids in Large HDL,39585,-0.198168514534822,0.00567834592054068,-0.209298072539082,-0.187038956530562,4.41480866467854e-257
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23561.Cholesterol in Large HDL,39585,-0.221806648171441,0.0059023021643292,-0.233375160413526,-0.210238135929356,4.79375256211463e-296
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23562.Cholesteryl Esters in Large HDL,39585,-0.228658674359185,0.00589834134540013,-0.240219423396169,-0.217097925322201,1.66880653712111e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23563.Free Cholesterol in Large HDL,39585,-0.193729689436542,0.00587837922359533,-0.205251312714788,-0.182208066158295,2.18171529050009e-230
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23564.Triglycerides in Large HDL,39585,-0.0146782384212409,0.0048820677839712,-0.0242470912778244,-0.00510938556465731,0.00264637576587892
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23565.Concentration of Medium HDL Particles,39585,-0.177705381597834,0.00518597021130234,-0.187869883211987,-0.167540879983682,3.01507169549016e-248
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23566.Total Lipids in Medium HDL,39585,-0.161189827902948,0.00512986836801578,-0.171244369904259,-0.151135285901637,3.0397996328844e-210
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23567.Phospholipids in Medium HDL,39585,-0.140765691639705,0.00507759634092184,-0.150717780467912,-0.130813602811498,3.37739806922118e-165
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23568.Cholesterol in Medium HDL,39585,-0.198331456240829,0.00522488461856447,-0.208572230093216,-0.188090682388443,9.37721812451364e-302
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23569.Cholesteryl Esters in Medium HDL,39585,-0.200917803335154,0.00520780184872984,-0.211125094958664,-0.190710511711643,1.66963643978467e-308
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23570.Free Cholesterol in Medium HDL,39585,-0.180912210221479,0.00527765470450237,-0.191256413442304,-0.170568007000654,2.03362758300465e-248
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23571.Triglycerides in Medium HDL,39585,0.0580691178596851,0.0049192250668835,0.0484274367285935,0.0677107989907768,5.04942654886779e-32
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23572.Concentration of Small HDL Particles,39585,-0.0658952387489265,0.00488041041321632,-0.0754608431588305,-0.0563296343390225,2.58620550649076e-41
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23573.Total Lipids in Small HDL,39585,-0.0538202345752689,0.00491078876376503,-0.0634453805522483,-0.0441950885982894,7.53754876150854e-28
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23574.Phospholipids in Small HDL,39585,-0.0573968115047967,0.00491445799692107,-0.067029149178762,-0.0477644738308314,2.19500741614323e-31
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23575.Cholesterol in Small HDL,39585,-0.0818458206293099,0.00485863578827885,-0.0913687467743364,-0.0723228944842833,4.05168160460114e-63
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23576.Cholesteryl Esters in Small HDL,39585,-0.0811266128988185,0.00484115245508584,-0.0906152717107867,-0.0716379540868502,1.73251776959301e-62
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23577.Free Cholesterol in Small HDL,39585,-0.0739206655017431,0.00494482308868131,-0.0836125187555584,-0.0642288122479277,3.49081864573608e-50
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23578.Triglycerides in Small HDL,39585,0.130734901593191,0.00522613483212935,0.120491677322217,0.140978125864164,1.81637368842269e-135
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23579.Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,38832,0.0386030881675273,0.00497419610030239,0.0288536638109346,0.04835251252412,8.9922440877832e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23580.Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,38832,-0.0459556680834301,0.00496286741436394,-0.0556828882155835,-0.0362284479512768,2.31896624444399e-20
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23581.Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,38832,-0.0278075190549792,0.00493139046072066,-0.0374730443579917,-0.0181419937519667,1.74252122881969e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23582.Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,38832,-0.0662914063282972,0.00502993790042502,-0.0761500846131303,-0.0564327280434642,1.91263865330976e-39
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23583.Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage,38832,0.0232845947758617,0.00487780834461254,0.0137240904204212,0.0328450991313023,1.82693132021473e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23584.Phospholipids to Total Lipids in Very Large VLDL percentage,39401,0.0841161430557529,0.00478420712913759,0.0747390970826432,0.0934931890288626,1.55696351004054e-68
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23585.Cholesterol to Total Lipids in Very Large VLDL percentage,39401,-0.10002703067552,0.00533131518122737,-0.110476408430726,-0.0895776529203143,1.10971463437546e-77
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23586.Cholesteryl Esters to Total Lipids in Very Large VLDL percentage,39401,-0.106920494674575,0.00530241313653728,-0.117313224422188,-0.0965277649269617,2.77709804484305e-89
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23587.Free Cholesterol to Total Lipids in Very Large VLDL percentage,39401,-0.0421836407586815,0.00515266266012651,-0.0522828595725294,-0.0320844219448335,2.89006303858296e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23588.Triglycerides to Total Lipids in Very Large VLDL percentage,39401,0.0595817760888859,0.00520971714662634,0.0493707304814983,0.0697928216962735,3.62066129009142e-30
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23589.Phospholipids to Total Lipids in Large VLDL percentage,39581,0.14320328231053,0.00514044702184885,0.133128006147706,0.153278558473354,9.37017513089477e-167
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23590.Cholesterol to Total Lipids in Large VLDL percentage,39581,-0.0171700065839888,0.00506976740531777,-0.0271067506984117,-0.007233262469566,0.000709004942972151
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23591.Cholesteryl Esters to Total Lipids in Large VLDL percentage,39581,-0.0547196473059636,0.00526698695831679,-0.0650429417442645,-0.0443963528676627,3.35134262763511e-25
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23592.Free Cholesterol to Total Lipids in Large VLDL percentage,39581,0.066440288796543,0.00492237567209863,0.0567924324792297,0.0760881451138563,2.74314803440717e-41
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23593.Triglycerides to Total Lipids in Large VLDL percentage,39581,-0.0492100340993943,0.0048619599731904,-0.0587394756468475,-0.0396805925519411,5.25769269338126e-24
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23594.Phospholipids to Total Lipids in Medium VLDL percentage,39585,-0.0458149892251604,0.00531211127047832,-0.0562267273152979,-0.0354032511350229,7.03586005691326e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23595.Cholesterol to Total Lipids in Medium VLDL percentage,39585,-0.10281397541623,0.00547891986528457,-0.113552658352187,-0.0920752924802719,1.02259283871813e-77
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23596.Cholesteryl Esters to Total Lipids in Medium VLDL percentage,39585,-0.11195949160084,0.00548608369968951,-0.122712215652231,-0.101206767549448,2.16576571420506e-91
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23597.Free Cholesterol to Total Lipids in Medium VLDL percentage,39585,-0.0728466720033249,0.00540643647288421,-0.0834432874901779,-0.0622500565164718,3.76043489794598e-41
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23598.Triglycerides to Total Lipids in Medium VLDL percentage,39585,0.091342692472893,0.00545909552449025,0.0806428652448921,0.102042519700894,2.63964455141603e-62
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23599.Phospholipids to Total Lipids in Small VLDL percentage,39585,-0.090078134816829,0.00523428401805737,-0.100337331492221,-0.0798189381414365,9.05449707455215e-66
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23600.Cholesterol to Total Lipids in Small VLDL percentage,39585,-0.040990334472317,0.0051116445912893,-0.051009157871244,-0.03097151107339,1.14053865815199e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23601.Cholesteryl Esters to Total Lipids in Small VLDL percentage,39585,0.00320041153454994,0.00498900313219538,-0.006578034604553,0.0129788576736529,0.521211653761932
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23602.Free Cholesterol to Total Lipids in Small VLDL percentage,39585,-0.0995774141495612,0.0052640429242221,-0.109894938281036,-0.0892598900180859,6.2631541096057e-79
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23603.Triglycerides to Total Lipids in Small VLDL percentage,39585,0.0565808166599942,0.00515255319962593,0.0464818123887274,0.066679820931261,5.95103432418701e-28
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23604.Phospholipids to Total Lipids in Very Small VLDL percentage,39585,0.134299734293251,0.00504959331314248,0.124402531399492,0.14419693718701,1.73901657369176e-152
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23605.Cholesterol to Total Lipids in Very Small VLDL percentage,39585,-0.109469492655578,0.00536485799734517,-0.119984614330374,-0.0989543709807811,2.29868833284936e-91
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23606.Cholesteryl Esters to Total Lipids in Very Small VLDL percentage,39585,-0.12079949235437,0.0054117865382509,-0.131406593969342,-0.110192390739398,1.1061605660525e-108
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23607.Free Cholesterol to Total Lipids in Very Small VLDL percentage,39585,-0.0113999765038941,0.00495356389971718,-0.0211089617473398,-0.00169099126044845,0.0213838156322983
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23608.Triglycerides to Total Lipids in Very Small VLDL percentage,39585,0.0869542232879684,0.00534026243866052,0.0764873089081938,0.097421137667743,3.98361356665995e-59
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23609.Phospholipids to Total Lipids in IDL percentage,39585,0.0692356177955702,0.00495026378072174,0.0595331007853555,0.0789381348057848,3.47912038991206e-44
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23610.Cholesterol to Total Lipids in IDL percentage,39585,-0.109959615276172,0.00513353153910822,-0.120021337092824,-0.0998978934595196,2.35849204692561e-100
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23611.Cholesteryl Esters to Total Lipids in IDL percentage,39585,-0.101636986196747,0.00507501638806474,-0.111584018317354,-0.09168995407614,4.0171725922785e-88
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23612.Free Cholesterol to Total Lipids in IDL percentage,39585,-0.0523216151955735,0.00508175726502412,-0.0622818594350208,-0.0423613709561262,8.80725839506819e-25
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23613.Triglycerides to Total Lipids in IDL percentage,39585,0.106908043945784,0.00519170655076305,0.0967322991062882,0.117083788785279,5.43011226790649e-93
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23614.Phospholipids to Total Lipids in Large LDL percentage,39585,0.0264059887362265,0.00496993177587077,0.0166649224555197,0.0361470550169332,1.09215459740605e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23615.Cholesterol to Total Lipids in Large LDL percentage,39585,-0.109068220236149,0.00514790895590871,-0.11915812178973,-0.0989783186825679,2.96672679912638e-98
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23616.Cholesteryl Esters to Total Lipids in Large LDL percentage,39585,-0.0171376472574867,0.00491755476575534,-0.0267760545983672,-0.00749923991660626,0.000493489399467397
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23617.Free Cholesterol to Total Lipids in Large LDL percentage,39585,-0.140621674122004,0.00540029865893749,-0.151206259493521,-0.130037088750486,2.19661171744671e-146
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23618.Triglycerides to Total Lipids in Large LDL percentage,39585,0.0892709533107625,0.00505262141448796,0.0793678153383661,0.0991740912831589,3.43170346490401e-69
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23619.Phospholipids to Total Lipids in Medium LDL percentage,39585,-0.0365154302629266,0.00492141394534894,-0.0461614015958106,-0.0268694589300427,1.23377424513725e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23620.Cholesterol to Total Lipids in Medium LDL percentage,39585,-0.0435869192846886,0.0051317769513103,-0.0536452021092568,-0.0335286364601204,2.18178409212881e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23621.Cholesteryl Esters to Total Lipids in Medium LDL percentage,39585,0.0918241335142994,0.00505418775437538,0.0819179255157236,0.101730341512875,5.16549704022494e-73
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23622.Free Cholesterol to Total Lipids in Medium LDL percentage,39585,-0.144671081993923,0.00522183136047095,-0.154905871460446,-0.1344362925274,5.41644800833337e-165
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23623.Triglycerides to Total Lipids in Medium LDL percentage,39585,0.0630005150838407,0.00496363588038342,0.0532717887582892,0.0727292414093922,9.86457830288278e-37
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23624.Phospholipids to Total Lipids in Small LDL percentage,39585,-0.038814770051982,0.00503794641212435,-0.0486891450197457,-0.0289403950842182,1.39184337281264e-14
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23625.Cholesterol to Total Lipids in Small LDL percentage,39585,-0.0474279830566098,0.00495233031038231,-0.0571345504649591,-0.0377214156482605,1.14580172187872e-21
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23626.Cholesteryl Esters to Total Lipids in Small LDL percentage,39585,0.0502228610671527,0.00503649147210214,0.0403513377818325,0.0600943843524729,2.37599116032883e-23
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23627.Free Cholesterol to Total Lipids in Small LDL percentage,39585,-0.103969060385532,0.00502028546071444,-0.113808819888533,-0.094129300882532,5.06523784167228e-94
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23628.Triglycerides to Total Lipids in Small LDL percentage,39585,0.0979323963711349,0.00505848341820666,0.0880177688714498,0.10784702387082,1.52997904217021e-82
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23629.Phospholipids to Total Lipids in Very Large HDL percentage,39580,-0.0932209074785618,0.00557046008627615,-0.104139009247663,-0.0823028057094605,2.52711480208676e-62
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23630.Cholesterol to Total Lipids in Very Large HDL percentage,39580,0.0140324280040621,0.00514806744943447,0.00394221580317054,0.0241226402049537,0.00642234682243694
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23631.Cholesteryl Esters to Total Lipids in Very Large HDL percentage,39580,-0.0945232198013776,0.00484675798117313,-0.104022865444477,-0.0850235741582783,1.02087676059709e-83
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23632.Free Cholesterol to Total Lipids in Very Large HDL percentage,39580,0.171747550053202,0.00576533704397227,0.160447489447016,0.183047610659387,9.55408148117767e-190
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23633.Triglycerides to Total Lipids in Very Large HDL percentage,39580,0.132670608396341,0.00538958567470512,0.122107020473919,0.143234196318763,2.56996395290354e-131
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23634.Phospholipids to Total Lipids in Large HDL percentage,39585,0.094400212160471,0.00546587714528424,0.0836870929557139,0.105113331365228,3.18358621510679e-66
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23635.Cholesterol to Total Lipids in Large HDL percentage,39585,-0.148609358025801,0.00550100407733953,-0.159391326017386,-0.137827390034215,3.72732312608839e-157
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23636.Cholesteryl Esters to Total Lipids in Large HDL percentage,39585,-0.147442915257391,0.00530264769855482,-0.157836104746558,-0.137049725768224,3.78089938562123e-166
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23637.Free Cholesterol to Total Lipids in Large HDL percentage,39585,-0.0375015418655024,0.00553209544932345,-0.0483444489461764,-0.0266586347848284,1.25398613525128e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23638.Triglycerides to Total Lipids in Large HDL percentage,39585,0.14451710766685,0.00519431512479799,0.134336250022246,0.154697965311454,2.4308845776623e-166
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23639.Phospholipids to Total Lipids in Medium HDL percentage,39585,0.209756541238067,0.00529920373808794,0.199370101911415,0.220142980564719,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23640.Cholesterol to Total Lipids in Medium HDL percentage,39585,-0.192419860782057,0.00522289622414861,-0.202656737381389,-0.182182984182726,4.47628638218164e-285
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23641.Cholesteryl Esters to Total Lipids in Medium HDL percentage,39585,-0.15997630162203,0.00504342798139864,-0.169861420465571,-0.150091182778489,4.34075911135799e-214
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23642.Free Cholesterol to Total Lipids in Medium HDL percentage,39585,-0.196856863276947,0.00566305429819533,-0.20795644970141,-0.185757276852484,3.76487853598598e-255
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23643.Triglycerides to Total Lipids in Medium HDL percentage,39585,0.163621371292173,0.00512883265604636,0.153568859286322,0.173673883298024,1.84613942102038e-216
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23644.Phospholipids to Total Lipids in Small HDL percentage,39585,-0.0316018980112508,0.00494786374204658,-0.0412997109456621,-0.0219040850768395,1.73946711475984e-10
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23645.Cholesterol to Total Lipids in Small HDL percentage,39585,-0.083117502715307,0.00487864385041305,-0.0926796446621166,-0.0735553607684975,1.65418910798942e-64
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23646.Cholesteryl Esters to Total Lipids in Small HDL percentage,39585,-0.0655251296912789,0.00480570812947006,-0.0749443176250402,-0.0561059417575176,4.31142316891913e-42
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23647.Free Cholesterol to Total Lipids in Small HDL percentage,39585,-0.0632876299017186,0.00534434781353613,-0.0737625516162495,-0.0528127081871878,3.24564178027162e-32
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,NMR metabolomics,X23648.Triglycerides to Total Lipids in Small HDL percentage,39585,0.184628218916713,0.00521894110532473,0.174399094350277,0.19485734348315,7.62217896054146e-264
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24003.Nitrogen dioxide air pollution; 2010,51212,-0.00344449210399416,0.00429630840361616,-0.0118652565750818,0.00497627236709351,0.422714403752049
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24004.Nitrogen oxides air pollution; 2010,51212,-0.00317675476291433,0.00419993234094666,-0.0114086221511698,0.00505511262534113,0.449426491738567
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24005.Particulate matter air pollution (pm10); 2010,49293,-0.00723905520074479,0.00405592519633665,-0.0151886685855646,0.000710558184075041,0.0743040817559329
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24006.Particulate matter air pollution (pm2.5); 2010,49293,0.00191524176358323,0.00438061569411554,-0.00667076499688324,0.0105012485240497,0.661963966178708
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24007.Particulate matter air pollution (pm2.5) absorbance; 2010,49293,-0.0136454485966175,0.00435765401297803,-0.0221864504620544,-0.00510444673118051,0.00174187002801484
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24008.Particulate matter air pollution 2.5-10um; 2010,49293,-0.0144927468510851,0.00402124440807817,-0.0223743858909183,-0.00661110781125189,0.00031390056741835
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24009.Traffic intensity on the nearest road,51212,-0.127066853558597,0.0408588956431641,-0.207150289019199,-0.0469834180979956,0.00187346450061644
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24010.Inverse distance to the nearest road,51212,-0.00130443812878957,0.00375526563420119,-0.00866475877182391,0.00605588251424476,0.728321740766995
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24011.Traffic intensity on the nearest major road,51212,-0.000244965743928945,0.00379634018064024,-0.00768579249798382,0.00719586101012593,0.948551227151432
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24012.Inverse distance to the nearest major road,51212,-0.00655757494422167,0.00383555444183446,-0.0140752616502172,0.000960111761773871,0.0873362015385502
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24013.Total traffic load on major roads,51212,-0.0289622985134988,0.0277342775974842,-0.0833214826045678,0.0253968855775702,0.296365974789949
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24015.Sum of road length of major roads within 100m,51212,-0.0554038768892278,0.027083428324794,-0.108487396405824,-0.00232035737263152,0.0407979576405707
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24016.Nitrogen dioxide air pollution; 2005,51212,-0.00512499614454079,0.00430661874425635,-0.0135659688832832,0.00331597659420165,0.234045784103015
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24017.Nitrogen dioxide air pollution; 2006,51212,-0.00587616405315892,0.0043049421393542,-0.0143138506462932,0.00256152253997532,0.17227026183724
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24018.Nitrogen dioxide air pollution; 2007,51212,-0.00567473213994285,0.00426290880535342,-0.0140300333984355,0.00268056911854985,0.183138323965895
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24019.Particulate matter air pollution (pm10); 2007,51165,0.00588020932776647,0.0041347077207974,-0.00222381780499643,0.0139842364605294,0.154991694115485
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24020.Average daytime sound level of noise pollution,51212,-0.00948805775359944,0.00376612925382942,-0.0168696710911051,-0.00210644441609378,0.0117640642905682
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24021.Average evening sound level of noise pollution,51212,-0.00944279541936209,0.00376514178911831,-0.016822473326034,-0.00206311751269019,0.0121490543706194
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24022.Average night-time sound level of noise pollution,51212,-0.0094941597782001,0.00376613161479944,-0.016875777743207,-0.0021125418131932,0.0117101013756246
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24023.Average 16-hour sound level of noise pollution,51212,-0.00952500850169316,0.00376559716245592,-0.0169055789401068,-0.00214443806327955,0.0114286867050545
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24024.Average 24-hour sound level of noise pollution,51212,-0.00948997700002056,0.00376563494458381,-0.0168706214914048,-0.00210933250863628,0.0117360201568075
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2405.Number of children fathered,36056,0.00688785878273004,0.0295647390823393,-0.0510590298186549,0.064834747384115,0.815784368706949
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24500.Greenspace percentage, buffer 1000m",48106,0.000450187409509801,0.00445235052451404,-0.00827641961853772,0.00917679443755732,0.919462148814238
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24501.Domestic garden percentage, buffer 1000m",48106,0.00995882136962152,0.00406573064669729,0.00198998930209483,0.0179276534371482,0.0143143109641953
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24502.Water percentage, buffer 1000m",48106,-0.00941114994017294,0.00397373166776093,-0.0171996640089844,-0.00162263587136153,0.0178758752080114
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24503.Greenspace percentage, buffer 300m",48106,-0.00212009604799205,0.00420741953393348,-0.0103666383345017,0.00612644623851757,0.614340012937888
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24504.Domestic garden percentage, buffer 300m",48106,0.0108396258070281,0.00411155245808682,0.00278098298917797,0.0188982686248783,0.00838485486864253
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24505.Water percentage, buffer 300m",48106,-0.00448402711638881,0.00398468868289705,-0.012294016934867,0.0033259627020894,0.260467015511849
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24506.Natural environment percentage, buffer 1000m",51312,-0.00447935404925262,0.00424082522396555,-0.0127913714882251,0.00383266338971985,0.290865202676704
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,"X24507.Natural environment percentage, buffer 300m",51312,-0.00277610954800633,0.00400423104100572,-0.0106244023883775,0.00507218329236488,0.488130902902142
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X24508.Distance (Euclidean) to coast,51312,0.00311189409359269,0.00382985806231826,-0.00439462770855109,0.0106184158957365,0.416491701987686
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2684.Years since last breast cancer screening  or  mammogram,28594,0.0472155800109014,0.0457970091423362,-0.0425465579080776,0.13697771792988,0.302605124663431
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2704.Years since last cervical smear test,35446,0.00693551260587423,0.0280930166035238,-0.0481267999370325,0.061997825148781,0.805007985175421
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2714.Age when periods started (menarche),38747,-0.00438855833461888,0.0249198470865366,-0.0532314586242307,0.0444543419549929,0.860212314138366
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2734.Number of live births,39217,0.0194645368279159,0.0237723481288629,-0.0271292655046554,0.0660583391604872,0.412919526830909
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2744.Birth weight of first child,35395,-0.0627285828867297,0.0273534637486931,-0.116341371834168,-0.00911579393929128,0.0218509996366755
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2754.Age at first live birth,33411,-0.0296614761967289,0.00633884929842651,-0.0420856208216449,-0.017237331571813,2.91791372631961e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2764.Age at last live birth,33389,-0.0237961160224242,0.00636518444862389,-0.036271877541727,-0.0113203545031213,0.000186219598328296
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2794.Age started oral contraceptive pill,36961,-0.00868040699733782,0.00625485695398275,-0.020939926627144,0.00357911263246836,0.165225620083345
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2804.Age when last used oral contraceptive pill,35791,-0.00942699871031839,0.00551430690594855,-0.0202350402459776,0.00138104282534077,0.0873746045600173
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2867.Age started smoking in former smokers,29230,-0.00699244554979201,0.008400754937853,-0.0234579252279839,0.00947303412839988,0.405243245696658
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X28735.Feeling anxious, nervous or on edge over the last 2 weeks",36310,-0.00630192220429863,0.0321469151589682,-0.0693098759158763,0.056706031507279,0.844585930180514
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28736.Not being able to stop or control worrying over the last 2 weeks,36306,-0.0369311171614988,0.0359214575709536,-0.107337174000568,0.0334749396775703,0.303919282376999
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28737.Little interest or pleasure in doing things over the last 2 weeks,36327,-0.0160522686086648,0.0366659866623434,-0.0879176024668578,0.0558130652495282,0.661540840769514
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X28738.Feeling down, depressed or hopeless over the last 2 weeks",36298,0.00283424567557531,0.0356513933349118,-0.0670424852608518,0.0727109766120024,0.936637105251285
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28739.Difficulty with standing for long periods,36337,0.0649082542009548,0.0336126052350668,-0.000972452059776141,0.130788960461686,0.053497172473328
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28740.Difficulty with taking care of household responsibilities,36362,0.0483417627276495,0.0371696134030255,-0.0245106795422804,0.121194204997579,0.193428935326632
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28741.Difficulty learning a new task,36268,0.0338241345638401,0.0419146619391495,-0.0483286028368929,0.115976871964573,0.419695667407973
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28742.Difficulty with joining in community activities,35835,-0.0408382774089522,0.0405020203373437,-0.120222237270146,0.0385456824522414,0.313329771029108
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28743.Difficulty with being emotionally affected by health problems,36278,0.000161983524344646,0.0347604942084169,-0.0679685851241525,0.0682925521728417,0.99628195496715
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X28744.Difficulty with concentrating on doing something for ten minutes,36359,0.0184618006696583,0.0469374569799398,-0.0735356150110238,0.11045921635034,0.69408419299508
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2887.Number of cigarettes previously smoked daily,29080,0.026057916433117,0.0435622253961167,-0.0593240453432717,0.111439878209506,0.549747867723236
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2897.Age stopped smoking,29234,0.0596324866422298,0.0101361838465677,0.0397655663029571,0.0794994069815025,4.26902349140795e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#0.Mental health conditions experienced by first degree blood relatives_None of the above,35014,-0.00342232282587184,0.0120361192538196,-0.0270131165633583,0.0201684709116146,0.776156852733839
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#1.Mental health conditions experienced by first degree blood relatives_Depression,35014,0.00284075579903188,0.0129205891245347,-0.0224835988850562,0.02816511048312,0.825982098700276
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#3.Mental health conditions experienced by first degree blood relatives_Schizophrenia,35014,-0.0170409857714786,0.0436748451034695,-0.102643682174279,0.0685617106313216,0.696412005599573
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#4.Mental health conditions experienced by first degree blood relatives_Any other type of psychosis or psychotic illness,35014,-0.0177650163387022,0.0424139426317681,-0.100896343896968,0.0653663112195633,0.675334920365016
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#5.Mental health conditions experienced by first degree blood relatives_A personality disorder,35014,0.0925602691532024,0.0458555823751933,0.00268332769782352,0.182437210608581,0.0435613390826449
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#7.Mental health conditions experienced by first degree blood relatives_Attention deficit or attention deficit and hyperactivity disorder,35014,-0.00472640964375731,0.0390417541231233,-0.0812482477250789,0.0717954284375643,0.903645390030269
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#8.Mental health conditions experienced by first degree blood relatives_An anxiety disorder,35014,0.0251111679082341,0.0178590739547279,-0.00989261704303269,0.0601149528595009,0.159730201911862
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29001#9.Mental health conditions experienced by first degree blood relatives_An eating disorder,35014,-0.0674535339595184,0.0329560595556126,-0.132047410688519,-0.00285965723051768,0.04070388004381
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29002.Recent lack of interest or pleasure in doing things,34942,0.00691783857526827,0.0370009241123843,-0.0656039726850049,0.0794396498355415,0.851692328793669
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29003.Recent feelings of depression,34938,-0.000518697793111169,0.035918745467211,-0.0709194389088448,0.0698820433226224,0.988478516459239
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X29004.Trouble falling or staying asleep, or sleeping too much",34949,0.0743212118328447,0.0295762346144729,0.0163517919884777,0.132290631677212,0.0119894409029522
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29005.Recent feelings of tiredness or low energy,34954,0.0954236069428842,0.0299068301518504,0.0368062198452574,0.154040994040511,0.00142325741756257
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29006.Recent poor appetite or overeating,34957,0.019189208589992,0.03931682906555,-0.0578717763784861,0.0962501935584701,0.62551271795237
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29007.Recent feelings of inadequacy,34922,-0.0394054393333013,0.0385382879310964,-0.11494048367825,0.0361296050116476,0.30656618665418
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29008.Recent trouble concentrating on things,34954,0.0227888332287096,0.0381474942793278,-0.0519802555587728,0.097557922016192,0.550260944555932
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29009.Recent changes in speed or amount of moving or speaking,34946,0.0169805943308247,0.0676298262310931,-0.115573865082118,0.149535053743767,0.801755797413695
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29010.Recent thoughts of suicide or self-harm,34882,-0.0192667663113448,0.0743752654920777,-0.165042286675817,0.126508754053128,0.795603017683755
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#0.Substances taken for depression_None of options listed,32598,1.15504090173632e-05,0.0234437443490934,-0.0459381885152058,0.0459612893332405,0.99960690456069
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#1.Substances taken for depression_Drugs or alcohol (more than once),32598,-0.0634461100550083,0.0413070793980608,-0.144407985675207,0.0175157655651908,0.124583872468827
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#2.Substances taken for depression_Medication prescribed to participant (for at least 2 weeks),32598,-0.015153657397879,0.0228992599204158,-0.060036206841894,0.029728892046136,0.508146885472577
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29038#3.Substances taken for depression_Unprescribed medication (more than once),32598,0.0384711593721038,0.064703930629124,-0.0883485446609791,0.165290863405187,0.552144851545118
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#1.Use of specific medications_Citalopram (sometimes called Cipramil),32598,-0.0431004856105551,0.0391369303559298,-0.119808869108178,0.0336078978870673,0.270807738245427
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#2.Use of specific medications_Fluoxetine (Prozac or Oxactin),32598,-0.00955129602744459,0.0421951138730553,-0.092253719218633,0.0731511271637438,0.820926545293119
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#3.Use of specific medications_Sertraline (Lustral),32598,-0.033638575960867,0.0477640346372982,-0.127256083849971,0.0599789319282374,0.481286029852807
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#5.Use of specific medications_Amitriptyline (Elavil),32598,0.0268833822382145,0.0595809171590689,-0.0898952153935604,0.14366197986999,0.651850892660501
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29039#7.Use of specific medications_Other antidepressant(s),32598,-0.0492267162942928,0.046530794578845,-0.140427073668829,0.0419736410802434,0.290112753403869
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29047#0.Activities undertaken to treat depression_None of options listed,32598,-0.0089777651129373,0.0236611080295398,-0.0553535368508353,0.0373980066249607,0.704376827286076
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#0.Manifestations of mania or irritability_None of options listed,32598,0.0104598542930456,0.0343506841899383,-0.0568674867192335,0.0777871953053248,0.760752670726846
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#1.Manifestations of mania or irritability_More active than usual,32598,0.0290122711582016,0.0543382005645617,-0.0774906019483393,0.135515144264742,0.593410222738871
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#2.Manifestations of mania or irritability_More confident than usual,32598,0.0446346172828035,0.0668268509905799,-0.086346010658733,0.17561524522434,0.504205863896237
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#3.Manifestations of mania or irritability_Easily distracted,32598,-0.0115927144695506,0.0411535171685874,-0.0922536081199819,0.0690681791808807,0.778184535505795
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#4.Manifestations of mania or irritability_More creative or had more ideas than usual,32598,0.0480391413272336,0.0696228686888452,-0.088421681302903,0.18449996395737,0.49021827520664
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#5.Manifestations of mania or irritability_Neded less sleep than usual,32598,0.0770007940382589,0.0664633205995097,-0.0532673143367801,0.207268902413298,0.246673076712335
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#6.Manifestations of mania or irritability_Thoughts were racing,32598,-0.0332592653522371,0.0359970765576169,-0.103813535405166,0.0372950047006919,0.355541239784005
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#7.Manifestations of mania or irritability_More restless than usual,32598,0.0261127269714346,0.0354770237391171,-0.043422239557235,0.0956476935001042,0.461722366423025
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29051#8.Manifestations of mania or irritability_More talkative than usual,32598,0.0894625278604106,0.0503865523665482,-0.00929511477802392,0.188220170498845,0.0758462210151732
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29058.Recent feelings or nervousness or anxiety,34784,0.00217709028376593,0.0344529168383304,-0.0653506267193617,0.0697048072868936,0.949616122095302
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29059.Recent inability to stop or control worrying,34790,0.0142328325880733,0.0360275564675202,-0.0563811780882663,0.0848468432644128,0.692810699600211
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29060.Recent worrying too much about different things,34783,-0.000644194267567812,0.0329733685026127,-0.0652719965326887,0.063983607997553,0.984413233471942
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29061.Recent trouble relaxing,34788,0.00309454716864689,0.034573996932557,-0.0646704868191648,0.0708595811564586,0.928682184489674
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29062.Recent restlessness,34791,0.048846541394099,0.0478603484787338,-0.0449597416242193,0.142652824412417,0.307463909316027
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29063.Recent easy annoyance or irritability,34776,-0.0271696830712598,0.0350553446840867,-0.0958781586520698,0.0415387925095502,0.43832626302505
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29064.Recent feelings of foreboding,34767,0.0300797521679236,0.0398994706185989,-0.0481232102445302,0.108282714580377,0.45093245205834
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#1.Symptoms of panic attack_Heart was pounding or racing,32598,0.00253089283429397,0.0235210047629353,-0.0435702765010591,0.0486320621696471,0.914314363789791
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#11.Symptoms of panic attack_Felt like things weren't real or detached from self,32598,0.0141015125289914,0.0386203665561017,-0.061594405920968,0.0897974309789507,0.715022082307004
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#12.Symptoms of panic attack_Afraid of losing control or 'going crazy',32598,-0.0597403793894852,0.0503190104477588,-0.158365639867092,0.038884881088122,0.235168082217475
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#13.Symptoms of panic attack_Afraid I was going to die,32598,0.0971608968615554,0.0569063161453355,-0.0143754827833021,0.208697276506413,0.0877863470124592
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#2.Symptoms of panic attack_Sweating,32598,0.0285756989444099,0.0353166420403941,-0.0406449194547625,0.0977963173435823,0.418463310387738
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#3.Symptoms of panic attack_Trembling or shaking,32598,0.0205365366461515,0.0381789987267336,-0.0542943008582463,0.0953673741505492,0.590658825187895
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#6.Symptoms of panic attack_Pain or discomfort in chest,32598,0.00257301719764641,0.0381210035011428,-0.0721441496645935,0.0772901840598863,0.946188349955531
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#7.Symptoms of panic attack_Nauseous or felt sick in the stomach,32598,0.032921345882946,0.034385479850897,-0.0344741946248122,0.100316886390704,0.338381799375488
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29065#9.Symptoms of panic attack_Felt hot or cold,32598,-0.000364111465170393,0.0465194455857562,-0.0915422248132526,0.0908140018829118,0.993755135418924
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29076.Felt loved as a child,34739,0.0149347268916234,0.0307020378948263,-0.045241267382236,0.0751107211654829,0.626664400782733
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29077.Physically abused by family as a child,34745,0.00238526845657133,0.0393890374852875,-0.0748172450145923,0.0795877819277349,0.951713404397372
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29078.Felt hated by family member as a child,34731,0.0343001012334117,0.0399719901718905,-0.0440449995034937,0.112645201970317,0.390854285848896
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29079.Sexually molested as a child,34652,0.0882453473903704,0.0543611061917124,-0.0183024207453858,0.194793115526127,0.104550716611725
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29080.Someone to take to doctor when needed as a child,34726,-0.0527945452453513,0.045925570825338,-0.142808664063014,0.0372195735723112,0.250347344315808
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29081.Stopped from seeing friends or family by partner or ex-partner as an adult,34733,0.0233788998920883,0.0540240793744457,-0.0825082956818254,0.129266095466002,0.665205260249779
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29082.Belittlement by partner or ex-partner as an adult,34675,0.0321557224251887,0.042961323955106,-0.0520484725268191,0.116359917377196,0.454186531774104
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29083.Physical violence by partner or ex-partner as an adult,34739,0.0299211347461474,0.0478977855128338,-0.0639585248590068,0.123800794351302,0.532189460797979
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29084.Sexual interference by partner or ex-partner without consent as an adult,34704,0.0380711940727766,0.0668177013308602,-0.0928915005357095,0.169033888681263,0.568840713921306
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29085.Sexual intercourse by partner or ex-partner without consent as an adult,34703,0.0277327443832462,0.0652002569837986,-0.100059759304999,0.155525248071491,0.670592058639441
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29086.Experienced a violent or sexual assault,34738,0.0270036303224507,0.0526753362043848,-0.0762400286381436,0.130247289283045,0.608211638518626
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29087.Experienced a life-threatening injury or illness,34746,0.0310003634268546,0.0371870443058596,-0.0418862434126302,0.103886970266339,0.404505871776214
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29088.Experienced a marital separation or divorce,34746,0.015302855716576,0.0332119443237165,-0.0497925551579084,0.0803982665910604,0.644977409926754
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29089.Experienced the death of a spouse or partner,34759,0.00755252179381861,0.0532813065712458,-0.0968788390858232,0.11198388267346,0.887281632608322
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29090.Experienced the death of a close friend or family member due to suicide,34744,-0.0572000959871954,0.0417071374542678,-0.13894608539756,0.0245458934231695,0.170256703083038
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29091.Frequency of drinking alcohol,34751,-0.291424544204891,0.0280132007335427,-0.346330417642634,-0.236518670767147,3.14994422570131e-25
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29092.Amount of alcohol drunk on a typical drinking day,33659,-0.266464541568589,0.0316466424940431,-0.328491960856914,-0.204437122280265,4.29305236945259e-17
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29093.Frequency of consuming six or more units of alcohol,33672,-0.277136567942385,0.0317863699248394,-0.339437852995071,-0.2148352828897,3.27004868822321e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29104.Ever used cannabis,34738,-0.0594395839119417,0.0368962061101567,-0.131756147887849,0.0128769800639653,0.107209949332846
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29108.Ever thought that life not worth living,34692,0.0480284936359146,0.0336788971230351,-0.0179821447252342,0.114039131997063,0.153876711141634
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29109.Ever contemplated self-harm,34711,0.0546096024301171,0.0433912711563392,-0.0304372890363077,0.139656493896542,0.208224009696189
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29111.Ever self-harmed,34728,0.143587204308507,0.0670229973083169,0.0122221295842062,0.274952279032808,0.0321868987295128
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29132.Ever had recurrent episodes of excessive overeating or binge eating,34734,0.0133959208290471,0.0479736112503519,-0.0806323572216427,0.107424198879737,0.780069644439847
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#1.Actions and feelings during periods of overeating or binge eating_Eaten much more rapidly than normal,33239,0.0675702782967551,0.0489558775244859,-0.0283832416512374,0.163523798244748,0.167549317562487
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#2.Actions and feelings during periods of overeating or binge eating_Eaten until feeling uncomfortably full,33239,0.0855955094486134,0.0380668159539911,0.0109845501787909,0.160206468718436,0.0245636399884003
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#3.Actions and feelings during periods of overeating or binge eating_Eaten large amounts of food when not physically hungry,33239,0.0993503173217726,0.0397864323798267,0.0213689098573122,0.177331724786233,0.0125387147182324
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29136#4.Actions and feelings during periods of overeating or binge eating_Eaten alone because of feeling embarrassed by overeating,33239,0.0830146875136337,0.0531840881033251,-0.0212261251688835,0.187255500196151,0.118582664526739
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,X29149.Dependency of self-esteem on body shape or weight currently,34727,-0.08239414476632,0.0314440193344187,-0.144024422661781,-0.0207638668708593,0.00879633344550854
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X29153.Pain or discomfort today,34742,0.0312101720755692,0.0301125203222326,-0.0278103677560068,0.0902307119071452,0.300014510742216
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29154.Anxiety or depression today,34742,0.00688610425090638,0.0366870117828646,-0.0650204388435082,0.0787926473453209,0.851116353522661
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29166.Frequency of confiding in someone close,34511,-0.0689895134236939,0.0289210437518579,-0.125674759177335,-0.0123042676700525,0.0170759284795709
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#0.Sports and social activities attended in person at least once a week_None of the above,34708,0.0207648206293917,0.0124987542423663,-0.00373273768564627,0.0452623789444298,0.0966718245291993
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#1.Sports and social activities attended in person at least once a week_Sports club or gym or fitness class,34708,-0.0375724661204527,0.0124282147330706,-0.061931766997271,-0.0132131652436344,0.00250735319132989
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#2.Sports and social activities attended in person at least once a week_Pub or social club,34708,-0.0625683575558365,0.0154397417902728,-0.0928302514647713,-0.0323064636469018,5.10435267744351e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#3.Sports and social activities attended in person at least once a week_Religious group,34708,0.0859163210135519,0.0184522396842176,0.0497499312324855,0.122082710794618,3.26007480848438e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#4.Sports and social activities attended in person at least once a week_Adult education class,34708,-0.0435408396912508,0.0285978033921797,-0.0995925343399229,0.0125108549574213,0.127907004867172
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29167#5.Sports and social activities attended in person at least once a week_Other group activity,34708,0.00844165326256088,0.0134569216291552,-0.0179339131305832,0.034817219655705,0.530469654014515
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#0.Sports and social activities attended virtually at least once a week_None of the above,34706,0.0296760624703146,0.0147508165451193,0.000764462041880697,0.0585876628987485,0.0442630638624491
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#1.Sports and social activities attended virtually at least once a week_Sports club or gym or fitness class,34706,-0.0400605618188976,0.0209630855291328,-0.0811482094559979,0.00102708581820263,0.0560302684578404
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#2.Sports and social activities attended virtually at least once a week_Pub or social club,34706,-0.0601023369538817,0.0333538171153207,-0.12547581849991,0.00527114459214691,0.0715790179770643
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#3.Sports and social activities attended virtually at least once a week_Religious group,34706,0.0228361778467621,0.0332207586901093,-0.0422765091858521,0.0879488648793764,0.49184106625301
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#4.Sports and social activities attended virtually at least once a week_Adult education class,34706,-0.050446759670518,0.0436989243666489,-0.13609665142915,0.0352031320881138,0.248354885315592
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X29168#5.Sports and social activities attended virtually at least once a week_Other group activity,34706,-0.0204067830354519,0.022123765935367,-0.0637693642687713,0.0229557981978675,0.356344698206113
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29171.Frequency of feeling 'in tune' with people,34525,0.0140469804004035,0.0355919547638383,-0.0557132509367196,0.0838072117375265,0.693096337328917
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29172.Freuency of feeling that lacks companionship,34660,0.0412552706194188,0.0326093423793974,-0.0226590404442001,0.105169581683038,0.205849684055398
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29173.Frequency of feeling left out,34616,0.0147620219427203,0.033534960269698,-0.0509665001858879,0.0804905440713285,0.659802565105124
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29174.Frequency of feeling isolated from others,34646,0.038734746620285,0.0345920557593898,-0.0290656826681189,0.106535175908689,0.262841647269178
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29175.Tendency to bounce back quickly after hard times,34725,-0.0295781441254168,0.0292063880853534,-0.0868226647727094,0.0276663765218758,0.311212377518531
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29176.Ability to make it through stressful events,34725,0.0283699216834292,0.0286752551940441,-0.0278335784968973,0.0845734218637557,0.322512978022152
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29177.Quick recovery from stressful events,34725,0.00299655701173798,0.0290283627029214,-0.053899033885988,0.0598921479094639,0.917783453640876
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29178.Hard to snap back when something bad happens,34725,-0.00298480958896128,0.0287209977784006,-0.0592779652346264,0.0533083460567039,0.917231341600418
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29179.Comes through difficult times with little trouble,34725,-0.033120618375218,0.0288909203022171,-0.0897468221675636,0.0235055854171276,0.251653972212483
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29180.Tendency to take a long time to get over setbacks,34725,-0.0206770822915159,0.0289288917425653,-0.0773777101069438,0.036023545523912,0.474775544362939
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29181.General happiness,34658,0.0418515686436656,0.0299390232233501,-0.0168289168741006,0.100532054161432,0.162173748913523
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,X29182.Belief that own life is meaningful,34553,0.0224765431742089,0.029746105216868,-0.0358258230508525,0.0807789093992702,0.449897920504574
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X2926.Number of unsuccessful stop-smoking attempts,28780,0.166982829209405,0.0428477983615524,0.0830011444207628,0.250964513998048,9.8639309187012e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2946.Father's age,33881,-0.0115037358257239,0.00916254766644689,-0.0294623292519598,0.00645485760051198,0.209320356913569
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X2966.Age high blood pressure diagnosed,28952,-0.0245727655425055,0.0147301870608686,-0.0534439321818079,0.00429840109679696,0.0953393000035395
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30000.White blood cell (leukocyte) count,50735,0.17617650911751,0.00377199326671468,0.16878340231475,0.183569615920271,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30010.Red blood cell (erythrocyte) count,50735,0.0152491946046148,0.00463361732271564,0.00616730465209211,0.0243310845571374,0.000999635629503603
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30020.Haemoglobin concentration,50735,-0.0251108739842109,0.00493897401209822,-0.0347912630479234,-0.0154304849204984,3.7159872182986e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30030.Haematocrit percentage,50735,-0.01780324105903,0.00483631571765638,-0.0272824198656366,-0.00832406225242353,0.000232631390891599
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30040.Mean corpuscular volume,50735,-0.0419480074276881,0.00391192663526369,-0.0496153836328049,-0.0342806312225712,8.98311571769382e-27
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30050.Mean corpuscular haemoglobin,50734,-0.04419244775832,0.00391918403635517,-0.0518740484695761,-0.0365108470470639,2.00922869583351e-29
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30060.Mean corpuscular haemoglobin concentration,50734,-0.014207069953101,0.00382665117265512,-0.021707306251505,-0.00670683365469694,0.000205503277794137
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30070.Red blood cell (erythrocyte) distribution width,50735,0.00739414071074381,0.00374024326336953,6.32639145395301e-05,0.0147250175069481,0.0480615130992284
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30080.Platelet count,50735,0.177361694122613,0.00380494328404402,0.169904005285887,0.184819382959339,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30090.Platelet crit,50735,0.175763507539454,0.00390841890803728,0.168103006479701,0.183424008599207,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30100.Mean platelet (thrombocyte) volume,50735,-0.0562512872046789,0.00379567123700888,-0.0636908028292163,-0.0488117715801415,1.71041963008951e-49
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30110.Platelet distribution width,50735,-0.0309314195226979,0.00376480839871354,-0.0383104439841764,-0.0235523950612193,2.19891215040465e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30120.Lymphocyte count,50697,0.205740238377849,0.00379574436760056,0.198300579417352,0.213179897338346,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30130.Monocyte count,50697,0.0967210904944127,0.00393178883640439,0.0890147843750601,0.104427396613765,3.70199419010738e-132
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30140.Neutrophill count,50697,0.110315826282162,0.00382578576166981,0.102817286189289,0.117814366375035,4.38653668486488e-180
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30150.Eosinophill count,50697,0.0862608664235776,0.00377715751648837,0.0788576376912604,0.0936640951558948,2.39629728221853e-114
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30160.Basophill count,50697,0.322667421139867,0.020680948975918,0.282132761147068,0.363202081132666,1.22371091345707e-54
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30170.Nucleated red blood cell count,50697,0.30022305012646,0.0850782724981316,0.133469636030122,0.466976464222798,0.000418167913605624
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30180.Lymphocyte percentage,50697,0.0652068524688595,0.00390078238059117,0.0575613190029008,0.0728523859348182,2.0624425031896e-62
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30190.Monocyte percentage,50697,-0.0345217380417325,0.00391838077690122,-0.0422017643644589,-0.0268417117190061,1.32304048767765e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30200.Neutrophill percentage,50697,-0.0523047573550175,0.00384933326200919,-0.0598494505485555,-0.0447600641614795,6.49381937275007e-42
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30210.Eosinophill percentage,50697,0.0294506405739666,0.00376013550502342,0.0220807749841207,0.0368205061638125,4.96513894584019e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30220.Basophill percentage,50697,-0.00698866107631734,0.00374902499032088,-0.0143367500573463,0.000359427904711575,0.0623146932800729
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30230.Nucleated red blood cell percentage,50696,0.295228734586837,0.0852459504459839,0.128146671712708,0.462310797460965,0.000534508074874989
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30240.Reticulocyte percentage,50260,0.0331112018968404,0.00401691439674485,0.0252380496792205,0.0409843541144603,1.7574349395553e-16
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30250.Reticulocyte count,50260,0.0362318388592441,0.00411884447434433,0.0281589036895293,0.044304774028959,1.49448268044873e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30260.Mean reticulocyte volume,50260,-0.033805409792315,0.00388869476820882,-0.0414272515380043,-0.0261835680466257,3.72268258854156e-18
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30270.Mean sphered cell volume,50260,-0.0440648518182798,0.00390697732109153,-0.0517225273676192,-0.0364071762689404,1.95696380634913e-29
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30280.Immature reticulocyte fraction,50260,0.0275108146280601,0.00405310317395732,0.0195667324071038,0.0354548968490165,1.1643259089509e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30290.High light scatter reticulocyte percentage,50260,0.0372675338561096,0.00410647250263974,0.0292188477509357,0.0453162199612835,1.21039851853936e-19
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30300.High light scatter reticulocyte count,50260,0.0394655609050891,0.00417620653727919,0.0312801960920218,0.0476509257181563,3.65621243528706e-21
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30500.Microalbumin in urine,31914,0.0121591457597838,0.00720470707524589,-0.00196208010769811,0.0262803716272658,0.0915139057745456
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30510.Creatinine (enzymatic) in urine,50859,0.0213015847136661,0.00401758725064382,0.0134271137024042,0.029176055724928,1.15387676142244e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30520.Potassium in urine,50796,-0.00407701200886668,0.00372743281703024,-0.0113827803302459,0.00322875631251259,0.274058841334055
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30530.Sodium in urine,50803,0.00142100752328675,0.00387282009338519,-0.00616971985974822,0.00901173490632173,0.713683042778661
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30600.Albumin,48114,-0.0553554886533327,0.00415628419985577,-0.06350180568505,-0.0472091716216154,2.50428914441946e-40
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30610.Alkaline phosphatase,50347,0.0597347301511568,0.00391979759176103,0.0520519268713051,0.0674175334310084,3.23411260077383e-52
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30620.Alanine aminotransferase,50338,0.0236636270650589,0.0041595344384759,0.0155109395656462,0.0318163145644717,1.29125907307844e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30630.Apolipoprotein A,47983,-0.222685971689775,0.00431123157919996,-0.231135985585007,-0.214235957794543,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30640.Apolipoprotein B,50190,0.0606588871572086,0.0039850542810856,0.0528481807662808,0.0684695935481364,4.238760887741e-52
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30650.Aspartate aminotransferase,50262,-0.00927763660953092,0.00391100700530041,-0.0169432103399197,-0.00161206287914212,0.0176903050759654
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30660.Direct bilirubin,46224,-0.0653399828845234,0.00424122834517065,-0.0736527904410579,-0.0570271753279889,2.80616853358976e-53
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30670.Urea,50337,-0.00433389008498996,0.00409720161209012,-0.0123644052446866,0.00369662507470668,0.290170727363514
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30680.Calcium,48111,0.0081045061923168,0.00405684244045625,0.000153095009022565,0.016055917375611,0.0457562781189178
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30690.Cholesterol,50352,-0.00735885490042897,0.00410961055717083,-0.0154136915924838,0.000695981791625859,0.0733616435883306
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30700.Creatinine,50341,-0.00397946129851398,0.00496378427139432,-0.0137084784704468,0.00574955587341889,0.422734240105384
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30710.C-reactive protein,50270,0.090196582012204,0.00423787903206236,0.0818903391093618,0.0985028249150462,1.11279215928944e-99
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30720.Cystatin C,50347,0.0754309777545824,0.00455646359383754,0.0665003091106609,0.084361646398504,3.00849574103645e-61
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30730.Gamma glutamyltransferase,50337,0.0231256958177796,0.00423657094070881,0.0148220167739904,0.0314293748615689,4.84241403452045e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30740.Glucose,48078,-0.00491306695647385,0.00413007421831826,-0.0130080124243776,0.00318187851142994,0.234221909477312
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30750.Glycated haemoglobin (HbA1c),50112,0.0820338754337764,0.00411224073508906,0.0739738835930018,0.0900938672745509,6.89774197963046e-88
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30760.HDL cholesterol,48093,-0.25280170731844,0.0045368785601032,-0.261693989296242,-0.243909425340637,0
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30770.IGF-1,50229,-0.00298243977558486,0.00404943303097167,-0.0109193285162893,0.00495444896511962,0.461428159976882
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30780.LDL direct,50296,0.0366911515898031,0.00406217662255604,0.0287292854095933,0.0446530177700129,1.79130592597741e-19
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30790.Lipoprotein A,45069,-0.01153353682292,0.0042450676091251,-0.0198538693368052,-0.00321320430903485,0.00659446804710127
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30810.Phosphate,48049,0.0444585395319125,0.00404911822767743,0.0365222678056648,0.0523948112581603,5.56504315485619e-28
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30830.SHBG,47867,-0.0757757390735418,0.00468818057633946,-0.0849645730031671,-0.0665869051439164,1.86828443043115e-58
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30840.Total bilirubin,50250,-0.0815532380271304,0.00395562918227802,-0.0893062712243954,-0.0738002048298655,1.05874433800359e-93
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30850.Testosterone,48225,-0.0347135144966492,0.00671372615661755,-0.0478724177636196,-0.0215546112296787,2.35276522616426e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30860.Total protein,48094,0.00695055328680128,0.00412213090203865,-0.00112882328119447,0.015029929854797,0.0917787438232911
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30870.Triglycerides,50328,0.14728366322925,0.00399346585643161,0.139456470150644,0.155110856307856,2.07438895094396e-290
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30880.Urate,50317,0.0213570134147653,0.00492113599183128,0.011711586870776,0.0310024399587546,1.43105646364077e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Blood and urine assays,X30890.Vitamin D,49277,-0.0233362578247708,0.00425082430553555,-0.0316678734636205,-0.0150046421859211,4.06190142052496e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3137.Number of measurements made,49399,-0.0125003143635667,0.0228423925974714,-0.0572714038546107,0.0322707751274773,0.584217334475601
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3143.Ankle spacing width,39626,-0.0043526568274707,0.00703707151229572,-0.0181453169915703,0.00944000333662892,0.536233373824376
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X3144.Heel Broadband ultrasound attenuation, direct entry",39625,-0.0090438910511972,0.0053989485851279,-0.0196258302780479,0.00153804817565348,0.0939303661568103
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3146.Speed of sound through heel,39626,-0.0215462758105193,0.00524278718020472,-0.0318221386837206,-0.011270412937318,3.98179323223977e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X3147.Heel quantitative ultrasound index (QUI), direct entry",39626,-0.0178267113234401,0.00529613592575047,-0.028207137737911,-0.00744628490896919,0.000764530954453218
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X3148.Heel bone mineral density (BMD),39617,-0.0177792568311561,0.00530104416251194,-0.0281693033896795,-0.00738921027263266,0.000798643600550901
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X3526.Mother's age at death,35109,-0.0045450560180611,0.00707127871318726,-0.0184047622959081,0.00931465025978594,0.520400200207672
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X3581.Age at menopause (last menstrual period),30252,-0.00575732289979497,0.00948419822947617,-0.0243463514295683,0.0128317056299783,0.543843461490905
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X3761.Age hay fever, rhinitis or eczema diagnosed",30232,0.00580003438068518,0.0089533224146956,-0.0117484775521182,0.0233485463134886,0.517132444444501
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4100.Ankle spacing width (left),32619,-0.0122627220835218,0.00924573375836388,-0.030384360249915,0.00585891608287145,0.184771153717225
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4101.Heel broadband ultrasound attenuation (left),32618,-0.00523195210199009,0.00716098337727445,-0.019267479521448,0.00880357531746784,0.465031311838005
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4103.Speed of sound through heel (left),32619,-0.0128988515608957,0.00697763984232123,-0.0265750256518453,0.000777322530053914,0.0645495514523988
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4104.Heel quantitative ultrasound index (QUI), direct entry (left)",32619,-0.0105613427064045,0.0070446477285338,-0.0243688522543307,0.00324616684152178,0.133857542950662
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4105.Heel bone mineral density (BMD) (left),32612,-0.0101108405654999,0.00705747299353541,-0.0239434876328293,0.00372180650182949,0.151995550591151
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4106.Heel bone mineral density (BMD) T-score, automated (left)",32619,-0.0105854088340837,0.00704473156345341,-0.0243930826984523,0.00322226503028503,0.132978449910475
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4119.Ankle spacing width (right),32607,-0.00694304014340673,0.00906750008948237,-0.0247153403187922,0.0108292600319787,0.443871856501813
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4120.Heel broadband ultrasound attenuation (right),32607,0.0077471289721687,0.00721140807592496,-0.00638723085664423,0.0218814888009816,0.282723266927039
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4122.Speed of sound through heel (right),32607,-0.00221966837802361,0.00701535066516167,-0.0159697556817405,0.0115304189256933,0.751705230772857
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4123.Heel quantitative ultrasound index (QUI), direct entry (right)",32607,0.00106409453655704,0.00708793567656588,-0.0128282593895121,0.0149564484626262,0.88066743278293
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4124.Heel bone mineral density (BMD) (right),32598,8.27274283421292e-05,0.00711087570594729,-0.0138545889553146,0.0140200438119988,0.990717942065437
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X4125.Heel bone mineral density (BMD) T-score, automated (right)",32607,0.00105984421339389,0.0070879557600522,-0.0128325490763084,0.0149522375030962,0.881140868949065
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4194.Pulse rate,32902,0.0337543598145781,0.0067322406375881,0.0205591681649054,0.0469495514642507,5.43680557878846e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4195.Pulse wave reflection index,32902,-0.00971541603162634,0.00660989750037162,-0.0226708151323547,0.00323998306910202,0.141642988600129
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4196.Pulse wave peak to peak time,32897,-0.0164130179456161,0.00712454671972606,-0.0303771295162792,-0.00244890637495307,0.0212604972666385
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4198.Position of the pulse wave peak,32902,0.0065411769291785,0.00680921036022971,-0.00680487537687173,0.0198872292352287,0.336760588559798
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4199.Position of pulse wave notch,32902,0.0173379291057828,0.00667955250123371,0.00424600620336473,0.0304298520082009,0.00945586773868302
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4200.Position of the shoulder on the pulse waveform,32902,0.0159113879490618,0.00697028355256152,0.00224963218604124,0.0295731437120824,0.0224684332972041
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4269.Number of triplets attempted (left),32771,-0.00489441470474051,0.105285289230003,-0.211253581595547,0.201464752186066,0.962923006529429
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4270.Volume level set by participant (left),32685,0.0239162130104434,0.0314956947330019,-0.0378153486662403,0.085647774687127,0.447664316300663
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4276.Number of triplets attempted (right),32778,0.00858492191476205,0.10322604975732,-0.193738135609585,0.210907979439109,0.933721229546636
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X4277.Volume level set by participant (right),32678,0.0452127542711338,0.0313445462068835,-0.0162225562943578,0.106648064836625,0.149212672643809
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X4288.Time to answer,32936,0.0035759264545101,0.00767790093562029,-0.0114727593793057,0.0186246122883259,0.641410846812901
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Cognitive function,X4290.Duration screen displayed,32936,-0.00313397092145027,0.00683182889957672,-0.0165243555646206,0.0102564137217201,0.646438416426617
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X46.Hand grip strength (left),51550,-0.039562686582394,0.0053613677957662,-0.0500709674620958,-0.0290544057026923,1.63699148162351e-13
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X47.Hand grip strength (right),51529,-0.0305739461471933,0.00531778369688655,-0.0409968021930909,-0.0201510901012956,9.05139446600283e-09
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X48.Waist circumference,51604,0.114691257557359,0.00838128905683936,0.0982639310059537,0.131118584108764,1.73408798285766e-42
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X4803.Tinnitus,32728,0.0772900055310411,0.0384519494345639,0.00192418463929579,0.152655826422786,0.0444570582818498
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X4825.Noisy workplace,32859,0.00452261247119945,0.0424644332560193,-0.0787076767105983,0.0877529016529972,0.915185221291131
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Working and living environment,X4836.Loud music exposure frequency,32799,0.0725584939612379,0.0451675725652947,-0.0159699482667398,0.161086936189215,0.108215033742879
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X49.Hip circumference,51601,-0.0211076393207962,0.00664742882351113,-0.034136599814878,-0.00807867882671436,0.00149840768155609
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X50.Standing height,51578,-0.0241120598306544,0.00526946358818004,-0.0344402084634873,-0.0137839111978215,4.76438100112355e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X5057.Number of older siblings,32078,-0.00197241525525827,0.0330369644261923,-0.0667248655305952,0.0627800350200786,0.952393408372337
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,X51.Seated height,51442,-0.00825019614048065,0.0048729172510141,-0.0178011139524683,0.001300721671507,0.0904531970341603
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5181.Ever had eye surgery,29991,-0.0300245497761764,0.0851043049328807,-0.196828987444623,0.13677988789227,0.724252709202546
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5186.Duration visual-acuity screen displayed (right),29976,-0.0195736394460626,0.00813201754119873,-0.0355123938268121,-0.00363488506531304,0.0161143049850915
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5188.Duration visual-acuity screen displayed (left),29974,-0.0186320096641485,0.00806080429274014,-0.0344311860779191,-0.0028328332503778,0.0208420329680053
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5190.Duration at which refractometer first shown (right),29923,-0.0231899608232797,0.00796762636467973,-0.038806508498052,-0.00757341314850743,0.00362137916399906
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5193.Duration at which refractometer first shown (left),29921,-0.0176038505126692,0.00798509619395098,-0.0332546390528131,-0.00195306197252524,0.0275204244214432
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5199.logMAR, initial (right)",29953,0.0219257765293153,0.0398979869169848,-0.0562742778279749,0.100125830886606,0.58265099396225
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5200.Final number of letters displayed (right),29953,0.272407116757654,0.327394726024423,-0.369286546250215,0.914100779765522,0.405416211979149
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5201.logMAR, final (right)",29899,0.00623435882422135,0.00772597185653994,-0.00890854601459693,0.0213772636630396,0.419735582434671
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5202.Number of rounds to result (right),29953,0.024684161805763,0.0383539368723902,-0.0504895544641218,0.0998578780756477,0.519866421493032
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5206.logMAR, initial (left)",29949,0.0245586103177484,0.0398900056609458,-0.0536258007777053,0.102743021413202,0.538143124733293
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5207.Final number of letters displayed (left),29949,-0.601700139660568,0.204169788281432,-1.00187292469217,-0.20152735462896,0.0032203079595191
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5208.logMAR, final (left)",29899,0.00032643555351613,0.00771520856206921,-0.0147953732281395,0.0154482443351718,0.966252447528995
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5209.Number of rounds to result (left),29945,0.0328358641174425,0.0384316013866633,-0.0424900746004176,0.108161802835303,0.392918477032417
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5254.Intra-ocular pressure, corneal-compensated (right)",29713,-0.0062974508093907,0.00808384164940044,-0.0221417804422156,0.00954687882343415,0.436001141205761
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5255.Intra-ocular pressure, Goldmann-correlated (right)",29713,-0.00322023564642515,0.00795938967169807,-0.0188206394029534,0.0123801681101031,0.685798665566601
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5256.Corneal hysteresis (right),29713,0.00467422792269234,0.00810879741588,-0.0112190150124325,0.0205674708578171,0.56434058498516
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5257.Corneal resistance factor (right),29713,0.000779190286352955,0.00797831496429222,-0.0148583070436598,0.0164166876163657,0.9222028315844
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5262.Intra-ocular pressure, corneal-compensated (left)",29696,-0.00852973175305142,0.00813590301825873,-0.0244761016688385,0.00741663816273568,0.294494880207605
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,"X5263.Intra-ocular pressure, Goldmann-correlated (left)",29696,-0.00984903815941163,0.00796125940424202,-0.025453106591726,0.00575503027290274,0.21609208222367
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5264.Corneal hysteresis (left),29696,0.00319997897498826,0.00807842218973972,-0.0126337285169016,0.0190336864668781,0.692035151799583
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X5265.Corneal resistance factor (left),29696,-0.00200147573434417,0.0079366706913285,-0.017557350289348,0.0135543988206597,0.800910220784863
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X5364.Average weekly intake of other alcoholic drinks,29813,0.3282437835948,0.140231359014403,0.05339031992657,0.60309724726303,0.0192789101345682
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#1.Never eat eggs, dairy, wheat, sugar_Eggs or foods containing eggs",51506,0.057363675320256,0.0229076750549224,0.0124646322126082,0.102262718427904,0.0122811884514767
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#2.Never eat eggs, dairy, wheat, sugar_Dairy products",51506,-0.0544854167730445,0.0257852557513588,-0.105024518045708,-0.00394631550038122,0.0346058170593099
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#3.Never eat eggs, dairy, wheat, sugar_Wheat products",51506,0.00588934298588513,0.0606203741110413,-0.112926590271756,0.124705276243526,0.92260701390555
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#4.Never eat eggs, dairy, wheat, sugar_Sugar or foods or drinks containing sugar",51506,-0.0479853959058265,0.010549476736314,-0.0686623703090019,-0.0273084215026511,5.42321354651724e-06
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Diet and food preferences,"X6144#5.Never eat eggs, dairy, wheat, sugar_I eat all of the above",51506,0.0322573125167285,0.00945807484582484,0.0137194858189119,0.0507951392145452,0.000649227629322454
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#3.Illness, injury, bereavement, stress in last 2 years_Death of a close relative",37607,-0.0177753389962281,0.0106679131343676,-0.0386844487395886,0.00313377074713243,0.0956877434704593
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#4.Illness, injury, bereavement, stress in last 2 years_Death of a spouse or partner",37607,-0.00342033380870219,0.0381487885424776,-0.0781919593519584,0.071351291734554,0.928560512773708
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#5.Illness, injury, bereavement, stress in last 2 years_Marital separation or divorce",37607,-0.0336399487042671,0.0182446533193274,-0.0693994692101489,0.00211957180161464,0.0652301489846449
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Mental health,"X6145#6.Illness, injury, bereavement, stress in last 2 years_Financial difficulties",37607,0.0046832294484467,0.0115266574462975,-0.0179090191462964,0.0272754780431898,0.684531790440705
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#1.Reason for glasses or contact lenses_For short-sightedness,51590,-0.0149115583121626,0.0215329428730391,-0.0571161263433193,0.0272930097189941,0.488629319694136
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#2.Reason for glasses or contact lenses_For long-sightedness,51590,-0.0149115583121626,0.0215329428730391,-0.0571161263433193,0.0272930097189941,0.488629319694136
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#3.Reason for glasses or contact lenses_For just reading or near work as you are getting older (called 'presbyopia'),51590,-0.0481057511154129,0.0157346802732136,-0.0789457244509115,-0.0172657777799143,0.002235478385763
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#4.Reason for glasses or contact lenses_For 'astigmatism',51590,-0.0923666610210619,0.0245958054219942,-0.14057443964817,-0.0441588823939534,0.000173430462579816
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#5.Reason for glasses or contact lenses_For a 'squint' or 'turn' in an eye since childhood (called 'strabismus'),51590,0.0822132497158146,0.06001646317155,-0.0354190181004235,0.199845517532053,0.170746394749309
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#6.Reason for glasses or contact lenses_For a 'lazy' eye or an eye with poor vision since childhood (called 'amblyopia'),51590,0.0225262299880516,0.0423935130648069,-0.0605650556189699,0.105617515595073,0.595173380129565
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Eye measures,X6147#7.Reason for glasses or contact lenses_Other eye condition,51590,0.13523620865355,0.0624191166275691,0.0128947400635146,0.257577677243585,0.0302751391274099
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#1.Mouth or teeth dental problems_Mouth ulcers,51505,-0.0216634411361463,0.0120053767789568,-0.0451939796229016,0.0018670973506091,0.0711672462468457
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#2.Mouth or teeth dental problems_Painful gums,51505,0.0395672941020176,0.0206938031315938,-0.00099256003590624,0.0801271482399414,0.0558819172324711
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#3.Mouth or teeth dental problems_Bleeding gums,51505,0.0118932275323748,0.010090916249906,-0.00788496831744086,0.0316714233821906,0.238564728705861
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#4.Mouth or teeth dental problems_Loose teeth,51505,0.0617795522889511,0.0190404980871134,0.0244601760382088,0.0990989285396935,0.00117739120084559
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#5.Mouth or teeth dental problems_Toothache,51505,0.0546180559774717,0.0164486194904133,0.0223787617762616,0.0868573501786818,0.000899645212686188
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6149#6.Mouth or teeth dental problems_Dentures,51505,0.0489423252736395,0.0134382932435655,0.0226032705162511,0.0752813800310279,0.000271017395928304
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#1.Vascular or heart problems diagnosed by doctor_Heart attack,29974,0.0586024355949705,0.0357557123382224,-0.0114787605879455,0.128683631777886,0.101271566108604
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#2.Vascular or heart problems diagnosed by doctor_Angina,29974,-0.0120939709385956,0.0310043883422543,-0.0728625720894139,0.0486746302122228,0.696496247109
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#3.Vascular or heart problems diagnosed by doctor_Stroke,29974,0.0481248625664513,0.0387158201435407,-0.0277581449148885,0.124007870047791,0.21390504734552
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6150#4.Vascular or heart problems diagnosed by doctor_High blood pressure,29974,-0.0295941439997474,0.032092289858763,-0.0924950321229229,0.0333067441234281,0.35648284391895
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#1.Fractured bone site(s)_Ankle,51458,0.0263595919829268,0.0334245385274852,-0.0391525035309443,0.0918716874967979,0.430335097817748
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#2.Fractured bone site(s)_Leg,51458,0.00724013806200923,0.0483718358706181,-0.0875686602444022,0.102048936368421,0.881020764372003
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#3.Fractured bone site(s)_Hip,51458,-0.00149299458357593,0.0995268649111853,-0.196565649809499,0.193579660642347,0.988031554483847
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#4.Fractured bone site(s)_Spine,51458,-0.063740031778521,0.0861891660726408,-0.232670797280897,0.105190733723855,0.459587591780722
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#5.Fractured bone site(s)_Wrist,51458,-0.0386798603662617,0.0309760852114653,-0.0993929873807337,0.0220332666482103,0.211785144108474
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#6.Fractured bone site(s)_Arm,51458,0.0823865553058602,0.039854245147978,0.00427223481582326,0.160500875795897,0.0387249449588819
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6151#7.Fractured bone site(s)_Other bones,51458,-0.0212026450747723,0.0162301013068266,-0.0530136436361524,0.0106083534866078,0.191434976796102
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#5.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Blood clot in the leg (DVT)",33417,0.00154910155024685,0.0315271603135775,-0.060244132664365,0.0633423357648587,0.960812370644729
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#6.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Emphysema or chronic bronchitis",33417,-0.011187860862635,0.0350557066535952,-0.0798970459036815,0.0575213241784115,0.749623377140908
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#7.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Blood clot in the lung",33417,0.00809869783714611,0.0456419843576929,-0.0813595915039319,0.0975569871782241,0.859166823724743
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6152#8.Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor_Asthma",33417,0.0241168303420802,0.0134616354814665,-0.00226797520159406,0.0505016358857545,0.0732410262822886
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#1.Medication for pain relief, constipation, heartburn_Aspirin",35551,-0.000109102076408546,0.0146304150032044,-0.0287847154826893,0.0285665113298722,0.994050189692874
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#2.Medication for pain relief, constipation, heartburn_Ibuprofen",35551,-0.0442526622677626,0.0118284726027298,-0.067436468569113,-0.0210688559664122,0.000184020719811495
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#3.Medication for pain relief, constipation, heartburn_Paracetamol",35551,0.0141022249005533,0.011710169078949,-0.00884970649418679,0.0370541562952934,0.228508971872271
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#4.Medication for pain relief, constipation, heartburn_Ranitidine",35552,0.0359115079848753,0.0284807982505728,-0.0199108565862474,0.091733872555998,0.207369158935915
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#5.Medication for pain relief, constipation, heartburn_Omeprazole",35552,0.0444287786255328,0.0185867917038728,0.00799866688594211,0.0808588903651236,0.0168484465300399
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,"X6154#6.Medication for pain relief, constipation, heartburn_Laxatives",35552,0.0376330211483923,0.023349338971213,-0.00813168323518522,0.0833977255319698,0.107045916446629
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#1.Vitamin and mineral supplements_Vitamin A,51505,-0.00801354302514995,0.0278810674558003,-0.0626604352385185,0.0466333491882186,0.773793820167648
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#2.Vitamin and mineral supplements_Vitamin B,51505,0.015780168791468,0.0182039192507143,-0.019899512939932,0.051459850522868,0.386028673814268
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#3.Vitamin and mineral supplements_Vitamin C,51505,0.044175569960094,0.0545486315321634,-0.0627397478429463,0.151090887763134,0.418040098659734
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#4.Vitamin and mineral supplements_Vitamin D,51505,-0.0289572584716386,0.0206475843575902,-0.0694265238125154,0.0115120068692383,0.16079136309748
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#5.Vitamin and mineral supplements_Vitamin E,51505,-0.0222472225746654,0.0225525834152643,-0.0664502860685834,0.0219558409192527,0.323916043242243
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#6.Vitamin and mineral supplements_Folic acid or Folate (Vit B9),51505,-0.0341172029193569,0.0250892570834242,-0.0832921468028683,0.0150577409641545,0.173893826486864
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6155#7.Vitamin and mineral supplements_Multivitamins + or - minerals,51505,-0.00872176080937414,0.00807641970653536,-0.0245515434341835,0.00710802181543516,0.280194195214108
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#1.Why stopped smoking_Illness or ill health,28008,0.00263042389936754,0.0275160171060584,-0.0513009696285069,0.056561817427242,0.923845981238899
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#2.Why stopped smoking_Doctor's advice,28008,0.0840850728587249,0.0350469835057096,0.015392985187534,0.152777160529916,0.0164743491478983
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#3.Why stopped smoking_Health precaution,28008,-0.0280549763154119,0.0256107673753374,-0.0782520803710733,0.0221421277402494,0.273388930653979
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6157#4.Why stopped smoking_Financial reasons,28008,0.0274025011428137,0.0212393468612872,-0.0142266187053093,0.0690316209909367,0.197061383453352
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#1.Pain type(s) experienced in last month_Headache,51639,0.0483943780653798,0.00867466531951478,0.0313920340391308,0.0653967220916287,2.44412316135034e-08
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#2.Pain type(s) experienced in last month_Facial pain,51639,0.0524845802899289,0.0256042639403313,0.00230022296687953,0.102668937612978,0.0403896589026265
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#3.Pain type(s) experienced in last month_Neck or shoulder pain,51639,0.00889041114190906,0.00875590208222573,-0.00827115693925337,0.0260519792230715,0.30994209471567
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#4.Pain type(s) experienced in last month_Back pain,51639,0.0149709550423477,0.00851595157570367,-0.00172031004603152,0.0316622201307269,0.0787602759946535
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#5.Pain type(s) experienced in last month_Stomach or abdominal pain,51639,0.0638049705377583,0.0122942603227519,0.0397082203051645,0.087901720770352,2.11979135671496e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#6.Pain type(s) experienced in last month_Hip pain,51639,-0.00116601409605715,0.0126795580308082,-0.0260179478364412,0.0236859196443269,0.926730361823554
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#7.Pain type(s) experienced in last month_Knee pain,51639,-5.87843043669137e-05,0.00938477762454105,-0.0184529484484674,0.0183353798397335,0.995002293935284
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6159#8.Pain type(s) experienced in last month_Pain all over the body,51639,0.0759864278382465,0.0266233242287472,0.023804712349902,0.128168143326591,0.00431867903961838
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#1.Leisure or social activities_Sports club or gym,42650,-0.0473769007157442,0.00925166407815617,-0.0655101623089303,-0.0292436391225581,3.07074654982399e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#2.Leisure or social activities_Pub or social club,42650,-0.0340721668121941,0.00972217839030044,-0.0531276364571829,-0.0150166971672052,0.000458390038094087
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#3.Leisure or social activities_Religious group,42650,0.0484521196701628,0.0116413628267931,0.0256350485296483,0.0712691908106773,3.16785231940909e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#4.Leisure or social activities_Adult education class,42651,0.0151351964508573,0.0159939831332749,-0.0162130104903614,0.0464834033920761,0.344004885486032
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Lifestyle factors,X6160#5.Leisure or social activities_Other group activity,42651,0.0238612599391253,0.0102639733878021,0.0037438720990333,0.0439786477792174,0.0200954730952962
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#1.Types of transport used (excluding work)_Car or motor vehicle,51403,0.0182580329442586,0.00958784296413464,-0.00053413926544529,0.0370502051539625,0.0568828418227201
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#2.Types of transport used (excluding work)_Walk,51403,-0.0179114920557523,0.00751760345087449,-0.0326459948194663,-0.00317698929203828,0.0171972936226056
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#3.Types of transport used (excluding work)_Public transport,51403,-0.0136299557014134,0.00897726052253455,-0.0312253863255811,0.00396547492275436,0.128956410990447
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6162#4.Types of transport used (excluding work)_Cycle,51403,-0.0461901470246227,0.0139611280967436,-0.0735539580942401,-0.0188263359550053,0.000939232919896263
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6164#1.Types of physical activity in last 4 weeks_Walking for pleasure (not as a means of transport),51419,-0.011772509065683,0.00825211463843061,-0.027946653757007,0.00440163562564098,0.153705073413366
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X6164#3.Types of physical activity in last 4 weeks_Strenuous sports,51419,-0.0750630194337473,0.0113153189270018,-0.0972410445306708,-0.0528849943368237,3.33316534418695e-11
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#1.Mineral and other dietary supplements_Fish oil (including cod liver oil),51505,0.0196759061175275,0.00871209242249603,0.00260020496943525,0.0367516072656197,0.0239247998811986
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#2.Mineral and other dietary supplements_Glucosamine,51505,-0.0163132742757625,0.0107267983769922,-0.0373377990946671,0.00471125054314215,0.128322423649425
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#3.Mineral and other dietary supplements_Calcium,51505,-0.033785874930491,0.0160631469180847,-0.065269642889937,-0.00230210697104502,0.035447162822839
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#4.Mineral and other dietary supplements_Zinc,51505,-0.0224919856253871,0.0187189461770981,-0.0591811201324993,0.0141971488817251,0.229543332642391
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#5.Mineral and other dietary supplements_Iron,51505,0.00155736691490516,0.0185159148203212,-0.0347338261329243,0.0378485599627347,0.932969869855502
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Health and medical history,X6179#6.Mineral and other dietary supplements_Selenium,51505,-0.0313054210053798,0.0264684855430482,-0.0831836526697544,0.0205728106589947,0.236921113600807
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical measures,"X78.Heel bone mineral density (BMD) T-score, automated",39626,-0.0178299615780219,0.00529616946714744,-0.0282104537336308,-0.00744946942241289,0.000762891935905497
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X864.Number of days or week walked 10+ minutes,51123,-0.0777191178594704,0.0178341500227225,-0.112674051904007,-0.0427641838149342,1.31807266350871e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X874.Duration of walks,47570,-0.0116442535981614,0.003910256994306,-0.0193083573070011,-0.00398014988932161,0.00290548531171593
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X884.Number of days or week of moderate physical activity 10+ minutes,50411,-0.0917302965546713,0.0173015450064826,-0.125641324767377,-0.0578192683419655,1.15547288135316e-07
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X894.Duration of moderate activity,44416,-0.0861742920203636,0.0208747383453429,-0.127088779177236,-0.0452598048634915,3.67117491495322e-05
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X90087.No-wear time bias adjusted average acceleration,30180,-0.0135579545274405,0.00781320814744689,-0.0288718424964364,0.00175593344155537,0.08274335132212
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X904.Number of days or week of vigorous physical activity 10+ minutes,50403,-0.141345084931295,0.0178999495934359,-0.176428986134429,-0.106261183728161,2.98124415809786e-15
PAG1,Phosphoprotein associated with glycosphingolipid-enriched microdomains 1,Physical activities,X914.Duration of vigorous activity,39526,-0.0155976098713921,0.00501849736723092,-0.0254338647111647,-0.00576135503161952,0.00188679931395538
